A microfluidics system for drug susceptibility testing in mycobacterium smegmatis. by Luthuli, Brilliant Bonisile.
 
 
A Microfluidics System for Drug Susceptibility 












Submitted in fulfilment of the requirement for the degree of Masters in the 
School of Laboratory Medicine and Medical Sciences 
 
       
i 
 
A Microfluidics System for Drug Susceptibility Testing in 
Mycobacterium smegmatis 
Brilliant Bonisile Luthuli 
 
A thesis submitted to the College of Health Sciences, University of KwaZulu-Natal, Medical School, 
for the degree of Master of Biomedical Sciences. 
This is a thesis in which a chapter is written as a set of discrete research paper, with an introduction 
and final discussion. This chapter would have been published in internationally recognized, peer-
reviewed journal. 
As the candidate’s supervisor, I have approved this thesis for submission. 
Supervisor: 




















I, Brilliant Bonisile Luthuli, declare as follows: 
1. The work described in this thesis has not been submitted to UKZN or other tertiary institution 
for purpose of obtaining an academic qualification, whether by myself or any other party. 
2. That my contribution to the project was as follows: 
I contributed to the design of the project, designed and manufacture the microfluidic chip and 
also performed all the experiment. 
 
 
 Bonisile Luthuli                                                       Date: November 2015 
















DETAILS OF CONTRIBUTION TO PUBLICATION that form part and/or include research 
in this thesis (include a publication that was published and give details of the contributions of 
each author to the experimental work and writing). 
 
Publication  
Luthuli BB, Purdy GE, Balagaddé FK (2015) Confinement-Induced Drug-Tolerance in 
Mycobacteria Mediated by an Efflux Mechanism. PLoS ONE 10(8): e0136231. 
doi:10.1371/journal.pone.0136231 
Bonisile Luthuli contributed to the design of the project, designed and manufactured the 
microdialyser chip, as well as its previous iterations. She performed all the experiments and 
contributed to the writing of the above publication. 



















I am sincerely grateful to my advisor Dr Frederick Balagaddé whose guidance, motivation 
and belief in me has made the journey as a Master’s student in research interesting and 
adventurous. Not only do I think he is the ideal supervisor, he has also been a great mentor. 
To him I am forever grateful. My gratitude also goes to the members of the Bioengineering 
Lab at KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) for their useful 
input and support.  I also thank Yashveer Ramlakhan for his assistance and engineering skills 
during the early days of my project. 
I express my gratitude to K-RITH for the unique opportunity of working with world class 
scientists. I am also indebted to everyone who wishes me well in everything I do whether in 
person or in secrete. 
A special thanks goes to my family for their undying love toward me from as long as I can 
remember, particularly, my grandmother for her genuine love, guidance and support. I thank 
my mother, for her everlasting love for me. I am truly blessed and grateful to have her in my 
life. 













TABLE OF CONTENTS 
AUTHOR’S DECLARATION ............................................................................................................... ii 
DECLARATION 1-PLAGIARISM ................................................................................................... ii 
DECLARATION 2-PUBLICATION ................................................................................................ iii 
ACKNOWLEDGEMENTS ................................................................................................................... iv 
LIST OF ABBREVIATIONS ............................................................................................................... vii 
ABSTRACT ........................................................................................................................................... ix 
Chapter 1 ................................................................................................................................................. 1 
LITERATURE REVIEW ....................................................................................................................... 1 
1.1 Tuberculosis Disease .................................................................................................................... 1 
1.1.1 Features of mycobacteria ....................................................................................................... 1 
1.1.2 Tuberculosis Disease Impact ................................................................................................. 3 
1.2 TB Treatment and Drug resistance ............................................................................................... 6 
1.2.1 Drug Susceptible TB Treatment ............................................................................................ 6 
1.2.2 Standard TB Treatment Regimen......................................................................................... 10 
1.2.3 Drug Resistant Tuberculosis ................................................................................................ 11 
1.2.4 Drug-resistant TB Treatment ............................................................................................... 13 
1.3 Currently Available TB Diagnostics and Drug Susceptibility Testing Tools ............................. 18 
1.3.1 Miscellaneous Tests ............................................................................................................. 18 
1.3.2 Phenotypic Methods ............................................................................................................. 19 
1.3.3 Genotypic Methods .............................................................................................................. 22 
1.4 Phenotypic and Genotypic DST .................................................................................................. 24 
Chapter 2 ............................................................................................................................................... 25 
MICROFLUIDICS ............................................................................................................................... 25 
2.1 Introduction to Microfluidics ...................................................................................................... 25 
2.2 Benefits of Microfluidics ............................................................................................................ 27 
2.3 Statement of Problem .................................................................................................................. 27 
2.4 Knowledge Gaps ......................................................................................................................... 28 
2.5 A Microfluidics Chip for Culturing Tuberculosis ....................................................................... 28 
2.6 Objectives ................................................................................................................................... 28 
2.7 Brief Thesis Overview ................................................................................................................ 28 
2.8 The Microdialyser Chip .............................................................................................................. 29 
2.8.1 Introduction .......................................................................................................................... 29 
2.8.2 Design and Fabrication ........................................................................................................ 29 
2.8.3 Characterization of Diffusive Mixing in a Micro-reactor of the Microdialyser ................... 31 
vi 
 
2.8.4 Modification of Microdialyser Chip .................................................................................... 32 
2.9 Macrophage Membrane Biology ................................................................................................ 33 
Chapter 3 ............................................................................................................................................... 35 
CONFINEMENT-INDUCED DRUG-TOLERANCE IN MYCOBACTERIA MEDIATED BY AN 
EFFLUX MECHANISM ...................................................................................................................... 35 
Supplementary Material .................................................................................................................... 52 
Supporting Information ..................................................................................................................... 58 
Chapter 4 ............................................................................................................................................... 69 
CONCLUDING REMARKS ................................................................................................................ 69 























LIST OF ABBREVIATIONS 
 
AIDS  Acquired Immuno Deficiency Syndrome 
ART  Antiretroviral therapy 
ATP  Adenosine Triphosphate 
CDC  Centre for Disease Control and Prevention 
CFU  Colony Forming Unit 
CO2  Carbon Dioxide 
DOTS  Directly observed therapy short course  
DST  Drug susceptibility tests 
DS-TB  Drug susceptible TB 
ELISA  Enzyme linked immunosorbent assay 
FDA  Food and Drug Administration  
HIV   Human Immunodeficiency  Virus 
katG  Catalase peroxidase enzyme 
KZN  KwaZulu-Natal 
LTBI  Latent TB Infection 
mAGP  Mycolyl arabinogalactanpeptidoglycan complex 
MBC  Minimum Bacterial Concentration 
MDR-TB  Multi-Drug Resistance- TB 
MGIT  Mycobacterial growth indicator tube 
MIC  Minimal inhibitory concentration 
mRNA  Messanger RNA 
MTB  Mycobacterium  tuberculosis 
MTBC  Mycobacterium tuberculosis complex 
NAD  Nicotinamide Adenine Dinucleotide 
PAO  Pyrazinoic acid  
PCR  Polymerase chain reaction 
PDMS  Polydimethylsoloxane 
PMMA  Polymethacrylate 
PS  Polystyrene 
QRDR  Quinolone Resistance Determining Region 
RRDR  Rifampicin resistant determining region 
rRNA   Ribosomal RNA 
RspA  Ribosomal protein S1  
TB  Tuberculosis  
viii 
 
XDR-TB  Extensively drug resistant-TB 






























Tuberculosis remains a major health concern worldwide. The emergence of strains resistant to anti-
tuberculosis drugs has further complicated management of this disease. In addition, the prolonged 
multidrug chemotherapy (6 to 9 months) required to effectively sterilize drug tolerant mycobacteria 
that persist in human tissues, impedes disease management efforts. Hence, drug susceptibility tests 
that can easily detect drug resistant strains in a minimal amount of time whilst detecting both genetic 
and phenotypic resistant mechanisms is one of the priorities of TB control programs. The aim of this 
project was to develop a culture-based drug susceptibility testing platform for tuberculosis using 
microfluidics technology. A microfluidic platform has many advantages such as large scale 
integration, high throughput screening, automation and requires minimal human involvement. Such 
qualities are ideal for a diagnostic test. 
We designed and built the microdialyser which is a physical cell culture system that has micro-sized 
cell culture chambers that are as small as 200 pL in volume, mimicking the volume of a membrane 
bound compartment of human macrophage—a cell that harbours TB bacilli. This system provides a 
unique advantage of performing drug susceptibility testing in a micro-sized environment which 
resembles an in vivo growth environment. With the miracle of miniaturization, the microdialyser can 
support 120 microdialyser units to operate independently. Since each microdialyser unit is very small 
it consume minimal reagents and therefore reduces costs.  
Each culture system is monitored in situ to provide automated, real time, non-invasive measurement 
of cell density. The microdialyser system was used to perform drug susceptibility tests using M. 
smegmatis cells. This system revealed an epigenetic drug-tolerant phenotype of M. smegmatis that 
appears when mycobacteria are cultured in a space-confined bioreactor and disappears in larger 
growth chambers with respect to rifampicin. We then investigated possible underlying mechanisms 
that caused the drug tolerance, which eluded detection in conventional culture systems. In view of 
these results we highly recommend that this system be further validated with M. tuberculosis isolates 








1.1 Tuberculosis Disease 
1.1.1 Features of mycobacteria 
 
The genus Mycobacterium is best known for its most pathogenic species—Mycobacterium 
tuberculosis—the causative agent of tuberculosis disease (TB), the world’s oldest and deadliest 
disease. A distinctive feature of pathogenic mycobacteria is their extremely slow growth. Under 
optimal conditions with sufficient oxygen and nutrients, the doubling time of M. tuberculosis can 
range from 18 to 24 hours depending on the specific factors of the growth environment 1. This is 
relatively long generation time for a bacterium. For instance, M. tuberculosis grows ~100 times 
slower than Clostridium perfringens, the fastest-growing bacteria on record with an average  
generation time of ~10 minutes 2. Interestingly non-pathogenic mycobacterial species generally have 
considerably faster growth rates. For instance, Mycobacterium smegmatis, a non-pathogenic 
mycobacterial species, has a generation time of 3 to 4 hours 3. As a result, mycobacteria have been 
traditionally classified into fast and slow growing species based on whether or not they produce 
visible growth colonies within 7 days 4,5. Since non-pathogenic species generally possess faster 
doubling times, compared to their pathogenic counterparts, the slow growth rate has been associated 
with pathogenesis in mycobacteria. 
M. tuberculosis and Mycobacterium leprae are both human pathogens with very slow growth rates 
(doubling times of ~24 hours and ~14 days respectively) 6. The mechanisms underlying their slow 
growth are currently unknown. Limited nutrient uptake has been associated with slow growth rate in 
pathogenic mycobacteria, however only a minimal increase in cell replication was observed when 
membrane permeability was increased 7. Limited RNA synthesis, which resulted in retarded protein 
synthesis, was found to be a more plausible factor in the slow growth rate of pathogenic 
mycobacteria. From that point onward mycobacteria were sub-divided into two taxonomic groups: 
slow growers with a single rRNA operon and fast growers with two operons 8,9. The correlation 
between growth rate and the number of rRNA operons per mycobacterial genome provided the best 
explanation for differences in the growth rate of mycobacterial species10. 
 
A distinctive feature of all mycobacterial species is a unique cell wall with high lipid content, 
comprised mostly of mycolic acids, cord factors and wax-D 11. The mycobacterial cell wall consists of 




acids, forming the mycolyl arabinogalactanpeptidoglycan complex (mAGP). The outer part of the cell 
wall is composed of free lipids, glycolipids and glycoproteins that are particularly rich in fatty acids 
such as peptidoglycan, phosphatidylinositol mannose, lipomannan, lipoarabinomannan, cord factors 
and wax-D.  
As is the case in almost all other known bacterial species, the peptidoglycan layer together with 
arabinogalactan is responsible for shape maintenance and cell wall structural integrity of 
mycobacteria 12. Meanwhile the lipid coating comprised of mycolic acids and glycoproteins bestows 
exclusive characteristics to mycobacteria—such as an impermeable outer membrane, extreme 
hydrophobicity, acid-fastness, resistance to harsh environments as well as a great variety of 
antimicrobial agents. These properties are also useful for long-term survival of mycobacteria under 
otherwise stressful conditions such as in the presence of lysozymes and oxygen radicals encountered 
in the phagocytic vacuole 13. 
 
Another feature of clinical importance in M. tuberculosis is its ability to become dormant by entering 
into a non-replicative state characterised by low metabolic activity and epigenetic drug resistance 
(derived from a physiological state and not genetic mutation) 14. This characteristic presents a major 
challenge for tuberculosis disease control given that current tools are by and large limited to detection 
and treatment of metabolically active mycobacteria. Most TB detection and drug susceptibility tools 
rely mainly on the ability of the M. tuberculosis to grow in order to be detected by colony forming 
units. These techniques are based on estimation of growth for a M. tuberculosis strain in the presence 
or absence of a drug. Liquid culture based techniques aimed for more rapid detection use the 
metabolic activities of growing bacteria. For instance BACTEC 460 and Mycobacteria Growth 
Indicator Tube (MGIT) can detect growth dependent changes such as CO2 and oxygen consumption, 
respectively. Techniques such as resazurin and tetrazolium bromide rely on M. tuberculosis to reduce 
nitrate to nitrite, 15 while phage-based techniques rely on the ability of mycobacteriophage to multiply 
in living mycobacterial cells 16. The application of the above mentioned techniques is limited to 
actively dividing bacterial cells. Dormant bacilli are also tolerant to killing by antimycobacterial 
agents. First line TB drug such isoniazid can only target metabolically active bacilli leaving behind 
dormant bacilli 17,18. These features have contributed to the success strategy of M. tuberculosis as a 
formidable pathogen for decades or even centuries, by allowing the microbes to withstand 





1.1.2 Tuberculosis Disease Impact 
1.1.2.1 Global Epidemiology 
 
TB remains one of the deadliest curable infectious diseases the world has ever encountered. It was a 
hard-learnt lesson when the disease, which had been pacified by antibiotics in both industrialised and 
developing countries, returned with full force during the early nineties. However, upon return it 
exerted a devastating impact fuelled by the prevailing HIV/AIDS epidemic. So severe was the 
devastation that it was immediately declared a global emergence by World Health Organisation in 
1993. An estimated 9 million people worldwide developed TB disease in 2013, which is a 26% 
increase from the 6.6 million cases reported in 1990 according to the  World Health Organisation19,20. 
Thirteen percent of the 9 million were HIV-positive. Of the 1.5 million people that died from TB in 
the same year, 25% (or 360 000) were HIV-positive. Africa as a region accounts for about 80% of the 
HIV-positive TB cases and TB deaths among people living with HIV 20. 
The brunt of the global TB cases were reported from South-East Asia, which accounted for more than 
half (55%) and Africa with 31%. India and China accounted for 24% and 11% of total cases, 
respectively. Meanwhile, the Americas (3%), East Pacific Mediterranean (6%) and European (5%) 
regions accounted for only a small fraction of the global disease burden 21. The top ten countries 
worldwide in terms of incidence were mostly in Africa with Swaziland, Lesotho and South Africa 
which ranked first, second and third, respectively. In these countries, estimates suggest that about 1 
person in every 100 (1000 per 100000 population) develops TB disease each year. 
 
TB infection manifests in two phases, as latent TB infection (LTBI) and active TB. TB infection is 
established when M. tuberculosis bacilli lands inside the alveolar macrophages in the lungs, which 
recruit other cells of the immune system to form a cage around the bacilli called a granuloma. The 
granuloma plays a role in maintaining the bacilli in a dormant state. By creating a physical enclosure 
around the mycobacteria and preventing them from disseminating to other areas outside the 
granuloma. In this state the tubercle bacilli can persist in the human host for years and even for the 
entire lifetime of the human. In LTBI, the patient does not become contagious and has no related 
symptoms or illness. Active TB on the other hand, is a symptomatic state of the disease whereby a 
patient can spread the disease to close contacts via airborne transmission. The typical symptoms of 
active pulmonary tuberculosis include fever, night sweats, weight loss, cough, and chest pains. In 
some instances, active TB patients may appear healthy and in others, they may become chronically ill. 
TB transmission occurs when a healthy person inhales aerosolized droplets containing M. tuberculosis 
bacilli released by a person with active TB when sneezing, laughing or coughing 22. Although persons 
with LTBI are not at risk of dying, the risk of advancing to active TB is estimated at 10% during one’s 
life time 23. In immune-compromised individuals, as in the case with HIV infection, this risk increases 




in the first two years after infection with tubercle bacilli. This risk is increased in children younger 
than four years; persons living with HIV, people with diabetes and other chronic conditions; as well as 
those using immunosuppressant medication 25. One third of world’s population is infected with latent 
form of TB which can progress at any time to an airborne and transmittable disease.  
 
The vast majority of people suffering with active TB are  adults during otherwise economically 
productive years of their lives (between 15 and 45 years of age), thereby causing large social and 
economic burdens to their respective countries 26,27. The disease has a particularly devastating effect 
on the livelihood of poverty-stricken families because of the relatively high costs associated with 
proper diagnosis and treatment as well as the opportunity cost associated with disease morbidity, 
resulting in less money earned to spend on food and nutrition. A majority of developing countries lack 
the systems required to ensure effective distribution of anti-TB chemotherapy. Such factors motivated 
the implementation of directly observed therapy short course (DOTS) as a component of World 
Health Organisation’s strategy for global TB control 28. 
DOTS is a strategy used to reduce the number of TB cases. In DOTS, healthcare workers observe 
patients as they take their medicine. Left to their own devices, many people with tuberculosis in 
resource-poor countries fail to take all their medication which contributes to the proliferation and 
spread of drug-resistant tuberculosis. DOTS ensures that the patient with TB completes therapy to 
maximize the cure outcome and to prevent drug resistance from developing in the community 29. 
DOTS functions by integrating government commitment, case detection, treatment regimen supply 
together with directly observed therapy, effective drug supply, and standardized assessment of 
treatment outcome 28. A cumulative total of 56 million people were successfully treated for TB 
between 1995 and 2012, as a result of this programme, which saved approximately 22 million lives 30. 
However, as much as DOTS has done appreciably well in other parts of the world, the incidence of 
TB continues to increase in sub-Saharan Africa, with public health incidence rates surpassing the 
1000 cases per 100,000 population mark20.  
1.1.2.2 The State Of Tuberculosis in South Africa 
 
Overall, 450, 000 cases of active TB and 40, 386 TB-related deaths were reported in 2013 in South 
Africa, making it the country with the third highest TB incidence in the world31. Statistics South 
Africa—an agency responsible for producing timely, accurate and official statistics including deaths, 
unemployment estimates in the country—ranked TB as the leading cause of death in the country in 
2013. This burden is partly attributed to conditions of poverty that favour transmission of the disease. 
For instance, most of the poor population resides in rural communities and informal crowded 
settlements, lacking essential facilities such as proper sanitation, clean water supply, medical services 
and electricity. Long distances to and from healthcare centres present a major barrier to the access of 




transport, including universal shared taxi and buses which are cheaper, for mobility. However, this 
mode of transportation increases the risk of TB transmission among the passengers given that the 
passengers are forced to sit in close proximity to each other and in many instances, such as in cold or 
rainy weather, they are operated with the windows closed and poor air circulation32. In crowded 
clinics during winter seasons, with closed windows and poor ventilation, patients seeking medical 
help may become infected with TB while waiting to receive medical attention in waiting rooms. 
Inadequate education and high level of unemployment in these communities drive people to commit 
petty crimes and end up in jail. Prisoners are often mixed together in confined settings that are ideal 
for the spread of TB. Prisons act as a reservoir for TB, pumping the disease into the community 
through staff, visitors and former inmates 33. However, the incidence and mortality patterns vary 
remarkably across the country, most likely because of substantial regional differences in the 
prevalence and distribution of health care systems and infrastructure. 
 
The high prevalence of HIV infection has played a decisive role in increasing and maintaining the 
high burden of TB in the country. In 2007 South Africa contained only 0.7% of world’s population, 
but shockingly had 17% of global burden of HIV 34. Currently, 60% of active TB cases are also co-
infected with HIV and 65% of those are from the KwaZulu-Natal province. TB infection in South 
Africa is highly concentrated in KwaZulu-Natal with 31% active TB cases followed by Eastern Cape 
(14%), Western Cape (14%) and Gauteng (13%) 35.  With the exception of urban areas, most 
communities in these provinces are normally served by a single community clinic without disease 
detection facilities. In the rural areas, people often live in homes which are scattered with long 
walking distances (10km on average) to the nearest healthcare facility. This also results in patients 
skipping clinic visits and foregoing TB medication. Since the clinics are highly overcrowded and 
medical staff are stretched too thin, there are scenarios where patients have to return home without 
receiving medical help after being turned away or told to return on the next day. Low levels of 
education in the rural communities also play a role in fuelling the TB burden. When confronted with 
illness, many patients will first exhaust all treatment options with local traditional healers before 
visiting a clinic or hospital 36. As a result, several weeks may pass by before a patient with active TB 
seeks proper medical attention. There is also an unfavourable perception associated with the typically 
negative attitude of healthcare workers in rural communities which has proved to be an obstacle for 
patients seeking TB treatment 37. 
 
Despite the comprehensive efforts made to lessen the TB burden such as the implementation of the 
DOTS strategy, only a treatment success rate of 74% was reported. The World Health Organisation 
had projected a much higher success rate well above 85%, considering that TB disease is curable with 
proper medical attention 38. Nonetheless, TB notifications increased two-fold during the same period. 




burdened countries 39, such as South Africa, which are characterized by high TB and HIV prevalence 
rates. In spite of being the wealthiest country in Africa, South Africa is far from meeting the target set 
by the Stop TB partnership and the Millennium Development Goal of reducing the prevalence and 
mortality rate of TB in half by 2015 relative to 1990 levels, according to the World Health 
Organisation TB report of 2014. This was an intermediate target meant to pave the way for a more 
ambitious goal of eliminating TB (defined by >1 case of TB disease per 1 million population) by 
2050. As long as a single TB patient can infect approximately 10 contacts before receiving treatment 
in a high HIV prevalence setting,40 it must be anticipated that each TB case will most probably yield 
another, fueling the epidemic 41. To comprehensively address the TB burden in South Africa, 
necessary factors including, health care facilities for TB treatment that are easily accessible with more 
powerful detection tools are required for better disease diagnosis and control. 
1.2 TB Treatment and Drug resistance 
In the 1940s streptomycin was discovered as the first antibiotic with a proven ability to kill M. 
tuberculosis 42. As a result, this drug was solely used in TB treatment until it was discovered that the 
use of a single agent in TB treatment can yield drug resistance. Ever since then, anti-TB 
chemotherapy research focused efforts on drug combination regimens capable of overcoming drug 
resistance 43. Today there are more than 10 drugs currently approved by the U.S Food and drug 
agency (FDA) for treating TB. These anti-TB drugs are categorised into two classes: First- and 
second-line drugs. First line drugs—including isoniazid, rifampicin, pyrazinamide and ethambutol—
have high potent activity against TB and form a core of TB treatment regimen. Second line drugs—
including fluoroquonolones and aminoglycosides—on the other hand are reserved for multi-drug 
resistance which is resistance to rifampicin and isoniazid. However, the second line drugs are in 
general more costly, less effective and more toxic than first line drugs 44. 
1.2.1 Drug Susceptible TB Treatment 
Drug susceptible TB is treated by the first line drugs which form the core of the TB treatment 
regimen. These include isoniazid (IHN), rifampicin (RIF), pyrazinamide (PZA) and ethambutol 
(EMB). 
Isoniazid (INH)  
Isoniazid (isonicotic acid hydrazide) is one of the most effective and commonly used anti-TB drugs. It 
has been a key drug in TB treatment since its introduction in 1952 45. Isoniazid is bactericidal, albeit 
only on actively growing tubercle bacilli, and is not active against non-replicating bacilli or under 
anaerobic conditions. INH enters the mycobacterial cells by passive diffusion. INH itself is non-toxic 
to the mycobacterial cell but acts as a pro-drug that is activated by the M. tuberculosis catalase-




oxygen radicals. These free radicals contribute to mycobacterial cell killing by damaging a variety of 
cellular components such as lipids, proteins and nucleic acids. However, the primary target of INH is 
NADH-dependent enoyl acyl carrier protein reductase, InhA, involved in fatty acid elongation in 
mycolic acid synthesis. 
Amongst the free radicals derived upon KatG mediated INH  activation is(isonicotinic acyl radical), a 
highly  reactive species that reacts with NAD bound within the active site of InhA forming an INH-
NAD adduct a tight binding inhibitor, causing NADH dissociation from InhA and therefore rendering 
the enzyme non-functional 47,48. 
Genetic studies characterised INH susceptible strains by a functional katG gene and at the same time, 
deletion of the katG gene resulted in transformation of INH susceptible strains to INH resistant 
strains. INH resistant clinical isolates of M. tuberculosis often lose catalase and peroxidase enzymes 
encoded by katG gene in high level resistant strains (MIC > 5 µg/ml). Depending on the type of 
mutation, and the degree to which function of the KatG enzyme is preserved, the MIC of isoniazid 
may range from 0.2 to 256 g/mL. 
INH resistance may also arise from mutations in the inhA gene or its promoter reducing affinity of 
isonicotinic acyl radical for NADH. Overexpression of InhA may also result in INH resistance. 
Mutations in InhA gene also cause resistance to the structurally related second line drug ethionamide. 
However these mutations usually confer low level resistance with MIC ranging from 0.2 to 1 g/mL. 
Several mutations that confer resistance to INH outside the inhA and katG regions (genes) have been 
reported. These include the mutation in the ndh region which codes for NADH dehydrogenase which 
has also been observed in ethiomide resistant strains. Mutations in this gene cause changes in the 
NADH dehydrogenase structure which hinders INH-NAD adduct from binding to the inhA active site. 
A mutation in ahpC, a gene that codes for alkayl hydroperoxidase reductase was also found to confer 
resistance to INH. However, these mutations only confer resistance in less than a quarter of clinical 
isolates that are INH resistant. 
Resistance to isoniazid is predominantly associated with mutations in katG. Although the frequency 
of isoniazid associated mutations varies with geographic region, population and genotype 49. About 
75% of INH resistance originates from katG gene mutations. Therefore most drug susceptibility test 
methods for INH resistance focuses on detection of mutations in the katG gene. This implies that 25% 
of INH resistance may be overlooked. 
Rifampicin (RIF) 
Rifampicin is a semi-synthetic drug that has demonstrated an excellent sterilizing activity against 




dependent RNA polymerase (RpoB)—the enzyme responsible for RNA transcription—resulting in 
inhibition of mycobacterial messenger RNA elongation and thereby killing the organism 51. A key 
feature of rifampicin is its potency against both actively growing and slow growing bacilli 52. This 
feature is a major factor of the drug’s ability to shorten TB treatment from 12-18 months to 9 months. 
Rifampicin has a few adverse reactions, which include pigmentation of body secretions such as urine, 
tears and sweat to orange-red and gastro intestinal upset 53. Due to its efficient activity, rifampicin 
together with isoniazid are considered the backbone of TB treatment. 
Rifampicin mono-resistance in M. tuberculosis is very rare. Rifampicin resistance generally serves as 
a marker for dual resistance to both isoniazid and rifampicin which is multi-drug resistance (MDR-
TB). The great majority of M. tuberculosis clinical isolates resistant to rifampicin show mutations in 
rpoB gene that encodes the B-subunit of RNA polymerase. Mutations in this gene result in 
conformational changes in the enzyme structure and thereby present a low affinity for the drug which 
leads to resistance 54. The vast majority of RIF resistance is caused by mutations found in the 81 base 
pair region of rpoB gene also known as rifampicin resistance-determining region (RRDR). Mutations 
in this region have been found in about 96 % of rifampicin-resistant M. tuberculosis isolates. 
Mutations at positions 531, 526 and 516 are among the most frequent mutations in RIF-resistant 
strains 55. Present-day, detection of mutations that cause rifampicin resistance serves as a rapid 
screening for MDR-TB as RIF resistance has been found to be highly correlated with MDR-TB 56,57. 
Some studies have reported RIF resistance with no mutation in the 81 base pair region of the rpoB 
gene suggesting unknown mutations and phenotypic factors as contributors to rifampicin resistance. 
Therefore, phenotypic methods remain an important component for drug susceptibility testing 58. 
Pyrazinamide (PZA) 
Pyrazinamide is a structural analogue of nicotinamide an active form of vitamin B3 that plays a role in 
energy production due to its role as a precursor of NAD, an important molecule involved in energy 
production. PZA is an important first-line anti-TB drug discovered in 1952. Its routine use in TB 
treatment reduced treatment duration time from the previous 9-12 months to the current 6 months 
which is now known as short course therapy. Its potent sterilizing activity and treatment-shortening 
potential is attributed to its unique ability to target a population of persistent bacilli residing within 
acidic pH environment inside macrophage compartments that is not killed by other drugs. Unlike 
other anti-TB drugs, PZA has high sterilizing activity in vivo but no activity against bacilli under 
normal neutral conditions. This requirement of acidic condition for the activity of the drug makes 





PZA is a pro-drug that requires modification within the mycobacterial cells to its active form, 
pyrazinoic acid (POA) by an enzyme pyrazinamidase (PZase). PZA enters the cells by passive 
diffusion. POA produced within the cells reaches the cells surface and excreted through a weak efflux 
pump. Small protonated POA molecules are capable of diffusing back across the membrane 
accumulating inside the cells, resulting in a collapsed proton gradient, reduced membrane potential 
and affecting membrane transport. Intracellularly, POA has been found to target ribosomal protein S1 
(RspA). POA directly binds to RspA which result in the inhibition of trans-translation, a process 
involved in rescuing stall ribosomes during mRNA decoding, tagging truncated protein for 
degradation 59. PZA resistance is brought about by mutation in pncAthe gene encoding PZase 60. 
The majority of pncA mutations include point mutations, deletions, and insertions in a 561 base pair 
region of the open reading frame or in the 81-base pair region of its putative promoter 61. The majority 
of PZA resistant clinical strains have pncA gene mutations and a small percentage of resistant strains 
contain no mutations in pncA or its promoter suggesting alternative mechanisms of resistance such as 
limited uptake and enhanced efflux. Mutations in the rspA gene encoding RspA, the target of POA 
can also confer PZA resistance. In research studies they have shown that, conformational changes 
induced by mutations or sequence variation in the C-terminus of  RspA  abolished POA binding 
activity 62. 
Ethambutol (EMB)  
Ethambutol (EMB) was reported to have anti-TB activity in 1961 and is now part of the modern-day 
short course therapy for drug susceptible TB alongside INH, RIF and PZA. Similar to INH, EMB acts 
against actively growing bacilli and has minimal effect on non-replicating bacilli. 
Arabinosyltransferasean enzyme involved in arabinogalactan synthesis—is the target of EMB in M. 
tuberculosis. EMB disrupts biosynthesis of the cell wall component arabinogalactan. 
Arabinosyltransferase  enzyme is responsible for the polymerization of arabinose into arabinan of 
arabinogalactan. Overproduction of arabinosyltransferase leads to EMB resistance 63-66. 
EMB resistance in M. tuberculosis is usually associated with mutations in the embCAB operon. EmbB 
gene encoding arabinosyltransferase is organised into an operon with embC and embA in this order 
embCAB. These three genes share 65% amino acid identity and they all presumed to encode 
transmembrane proteins 67. Mutations in embB and embC, are responsible for EMB resistance 
particularly mutations in the embB306 codon, which have been used as a maker for EMB resistance in 
genomic drug susceptibility tests. However mutations in embB306 locus appear in only 60% of EMB 
resistant clinical strains. In addition, this mutation has also been observed in EMB susceptible clinical 
isolates. The exact role of the embB306 mutation  in EMB resistance is not clearly understood, since 
about 35% of EMB resistant strains do not possess mutations in the embB region suggesting presence 




1.2.2 Standard TB Treatment Regimen 
Centers for Disease Control and Prevention (CDC) recommends that all health providers who attempt 
to treat TB  must be knowledgeable to prescribe the standard treatment regimen and have the means to 
assess adherence to the regimen until treatment completion given that treatment failure may result in 
drug resistance and disease relapse 69. Newly diagnosed TB patients must receive a multi-drug 
regimen for a duration of 6 months. The standard treatment regimen is made up of an intensive phase 
lasting 2 months followed by a continuation phase that lasts for 4 months. During the intensive phase 
four drugs are recommended including isoniazid, rifampicin, pyrazinamide and ethambutol. This 
phase is reported to kill 99% of bacilli rendering patients non-infectious within approximately 10-14 
days with subsided symptoms. However some patients may not respond to treatment the same, and 
some patients can take two months to convert from sputum positive to sputum negative. In the 
continuation phase that takes place during the four remaining months, only 2 drugs—rifampicin and 
isoniazid—are used. These drugs  have a high sterilizing effect on eradicating all remaining bacilli.  
Although a 6 month regimen is the preferred option, an alternative continuation phase where 
ethambutol substitutes rifampicin can be used for 6 months thereby extending treatment duration time 
to 8 months. The shorter duration of continuation phase with rifampicin and isoniazid is more likely to 
fail especially in patients co-infected with HIV and that is where the 8 months regimen become useful 
70. The 8 month regimen may also be used in cases where treatment adherence cannot be assessed 
throughout the continuation phase. The recommended TB regimen in South Africa is INH, PZA, RIF 
and EMB in a fixed dose combination given 7 days a week for the first 2 months. If a patient is 
clinically improving and converted to smear negative at the end of the second month, they receive a 
fixed dose combination of INH and RIF given 7 days a week for 4 months 71. 
In cases where a TB patient returns after disease relapse or treatment failure after receiving the first 
treatment course i.e. patient sputum sample remains smear positive after 5 months or more, it is 
recommended that the patient sample undergoes drug susceptibility testing for at least isoniazid and 
rifampicin before getting access to MDR-TB treatment. Upon confirmation of MDR-TB, a standard 
MDR-TB regimen or individually customized regimen is then administered. MDR-TB regimen varies 
according to the drug susceptibility results. The standard MDR-TB regimen in case of rifampicin and 
isoniazid resistance is 8 months of pyrazinamide, kanamycin, ofloxacin, prothiomide and cycloserine 
followed by 12 months of ofloxacin, prothiomide and cycloserine. In MDR-TB treatment, the 
intensive phase is defined by the duration of treatment with an injectable agent. The injectable agent 
should be continued at least 4 months after the patient first became smear-or culture-negative. The 
continuation period is recommended to last for a minimum of 18 months after culture conversion from 
a sputum sample. Extension of therapy to 24 months may be indicated in chronic cases with extensive 




In cases where DST results take long, the standard MDR-TB regimen in South Africa comprises of at 
least 5 drugs: EMB, PZA, KAN, moxifloxacin, ETH and terizidone. The current SA guidelines 
recommend at least 6 months of injectable drugs, with treatment duration time up to 18 months after 
culture conversion 73. South Africa wallows in a status quo of persistently unsatisfactory clinical 
outcomes with less than 45% MDR-TB treatment cases reported successful 20. 
1.2.3 Drug Resistant Tuberculosis 
Drug resistant TB is caused by decreased susceptibility of the M. tuberculosis strain to one or more 
anti-TB drugs. The emergence of drug resistant TB strains has posed a major threat in global TB 
disease control. Drug resistant TB result from a spontaneous mutation of a gene encoding an anti-TB 
drug target or inappropriate programmatic or individual use of TB treatment. Patients who have never 
received TB treatment could develop drug resistance due to transmission of the drug resistant strain. 
Such resistance is referred to as “primary resistance’’. On the other hand, resistance that result during 
the course of TB treatment due to poor adherence is called an “acquired resistance”. Drug resistant TB 
was first observed shortly after administration of streptomycin to TB patients in late 1940s suggesting 
that the use of a single agent can easily confer drug resistance. 
MDR-TB is a disease caused by M. tuberculosis strains that are resistant to the two most potent first-
line anti-TB drugs, isoniazid and rifampicin. MDR-TB possesses a major problem on efforts made to 
combat TB disease globally. MDR-TB is difficult to treat compared to drug susceptible tuberculosis. 
It develops mainly from inappropriate use of drug-susceptible treatment options. A patient who 
develops active TB with MDR-TB may spread this form of TB to other people. Globally, it was 
estimated that 5% of TB reported cases had MDR-TB in 2013, of which 3.5% were treatment naïve 
and 20.5% previously treated TB cases. Drug resistance surveillance showed that an estimated 480 
000 people developed MDR-TB in 2013 and 210 00 people died 74. 
According to the World Health Organization reports, in 2013 the highest percentage of MDR-TB 
cases were in Europe and Asia. Among new cases, the highest MDR-TB estimates reported in Belarus 
(35.2%) and Republic of Maldova (23.7%). Previously treated cases of MDR-TB were highest in 
Belarus 54.5% and Kazakhstan 55%. MDR-TB cases in Africa remain under reported. New cases of 
MDR-TB were highest in DR Congo 2.6%, Ethiopia 1.6% and South Africa 1.8%. Low level of 
reported drug resistance in Africa may not be an accurate portrayal of reality due to lack of resources.  
Many countries in the African region have not completed a drug resistant survey to investigate levels 
of MDR-TB. Out of the 36 high TB burdened countries, only 26 have managed to generate drug 
resistance data through special surveys, where only half of them conducted surveys, between 2010 
and 2013. Currently 3 countries have not finished survey since mid-1900s Democratic Republic of 




Investigating drug resistance in Africa remains a challenge where routine DSTs are not accessible to 
all TB patients due to lack of laboratory capacity. As a result, this affects treatment outcome. This is 
evident by the lowest treatment outcome of MDR-TB cases in the African region of less than 50% 
compared to the Eastern Mediterranean region which scored the highest mark of 64%. TB is a curable 
and manageable disease, which the European region has shown, however with only the right resources 
in place. Thorough assessment of TB drug resistance is of urgent need in Africa. 
In 2012, news of the massive deployment of GeneXpert―a new rapid diagnosis and drug-
susceptibility testing system for TB―was received with high hopes by everyone concerned with 
detrimental impact TB has caused. This meant that more patients would have a same day diagnosis 
followed by treatment on the very same day. The benefits of GeneXpert primarily include a short 
turnaround time of 2 hours for detection of TB and drug resistance against rifampicin. However, these 
benefits did not translate to reduced severity of the overall TB related illness due to the high cost of 
the GeneXpert machine, which is too expensive for most stakeholders. Most rural clinics cannot 
afford the price. GeneXpert is also neither suitable nor practical at the present time especially in low 
and middle income countries. For a more in-depth discussion on GeneXpert see section 1.3.3.2. 
 
South Africa had an estimated burden of approximately 26 000 notified MDR-TB cases, situated on 
the 5th place among highly MDR-TB burden countries75. However, only 40% of diagnosed cases 
received MDR treatment in 2013, most likely because of resource constraints, creating an even major 
dilemma, fuelling extensively drug resistance TB. 
Poor management of MDR-TB has emerged to a newer form of resistance, extensively drug-resistant 
TB (XDR-TB). In XDR-TB, the M. tuberculosis strain is also resistant to rifampicin and isoniazid in 
addition to one of the fluoroquonolones and any of the second-line injectable drugs. XDR-TB 
detection relies on the capacity of available laboratory to reliably perform and detect in vitro 
resistance to rifampicin and isoniazid together with fluoroquinolone and second-line injectable drugs. 
Automated culture systems are recommended for second-line DST, which allows identification of 
XDR-TB from 4 to 9 weeks. However, liquid culture systems are labour intensive, expensive, time 
consuming and require specialised equipment and a well-serviced biosafety level 3 facilities, which 
most resource limited countries cannot afford. As a result, in 2012 only 5% of new bacteriologically 
confirmed DSTs were performed for first line TB drugs worldwide. Furthermore, DSTs for 
fluoroquinolones and second-line injectable drugs was performed for only 23% of patients with TB 
who were confirmed to have MDR-TB 76. From 2006 when the first cases of XDR-TB were 
announced, 100 countries in 2013 have reported at least one case of XDR-TB 74. According to the 
World Health Organisation out of 1269 XDR-TB patients reported in 2013, only 22% completed 




However, this report does not represent global magnitude since only 40 countries were able to report 
XDR-TB outcome.  
In South Africa 10% of MDR-TB cases are XDR, only 15% were successfully treated while 40% died 
and 36% were lost to follow up 20. Most XDR-TB cases in South Africa were detected in KwaZulu-
Natal (1298), Western Cape (230) and Eastern Cape (488) 77. In KZN 80% of patients with active TB 
are co-infected with HIV. This high mortality of XDR-TB patients in South Africa was partly 
associated with elevated levels due to HIV co-infection (270, 000) in TB patients 20. High HIV 
infection had shown to worsen XDR-TB cases when 52 out of 53 XDR-TB patients who were HIV 
infected died during the Tugela Ferry outbreak in KwaZulu-Natal. It was also reported that 55% of 
those XDR-TB patients had never received any TB treatment before showing that they were infected 
with already drug resistant strains of TB 78. Some studies have reported no significant difference in 
mortality rates between HIV positive patient on active ART from HIV negative patients, suggesting 
that antiretroviral treatment contribute towards a better outcome to those co-infected with HIV and 
XDR-TB 79. 
XDR-TB treatment is far more expensive, less efficacious and more toxic compared to treatment of 
drug susceptible TB. Clinical outcomes remain poor in South Africa, with a poor treatment success 
rate of less than 20% in XDR-TB patients compared to current success rate of less than 45% in MDR-
TB which is also poor 73. XDR-TB is very difficult to treat and associated with high mortality rate. 
Recent studies have demonstrated higher treatment success rates where six anti-TB drugs were used 
in intensive phase instead of four 80. XDR-TB treatment regimens are usually individualized based on 
drug-susceptibility testing and treatment may incorporate drugs on group 5 such as clofazimine and 
delamanid that are not yet approved in case four of the approved second line anti-TB drugs are less 
effective, although data on efficacy and safety of group 5 drugs is still limited 81,82.  
1.2.4 Drug-resistant TB Treatment 
First line therapy often fails to cure TB in the case of drug resistance. MDR-TB, defined as resistance 
to at least two first line drugs; INH and RIF, is currently one of the greatest concerns in TB control 
worldwide. Treatment of MDR-TB requires the use of second line drugs that are generally more 
difficult to acquire, more expensive and more toxic compared to first line drugs. The World Health 
Organization classified the existing anti-TB agents into 5 groups based on drug efficacy, potency, 
class and frequency of use against TB (Table 1). All TB regimens are designed from these groups 
according to whether the strain of M. tuberculosis is DS-TB, MDR-TB or XDR-TB. The following 






Table 1: World Health Organisation recommended grouping of anti-TB agents 
Group 
Number 
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Aminoglycosides including Kanamycin (KAN), Amikacin (AMK) and capreomycin (CAP)—a 
macrocyclic polypeptide isolated from Streptomyces capreolus—are important injectable drugs in the 
treatment of multidrug resistance TB. Although they descend from two different classes of antibiotics, 
they all apply their antimicrobial activity at the protein translation level. KAN and AMK are closely 
related drugs that have similar mechanism of action with CAP, which is associated with changes in 
ribosomal RNA. These drugs inhibit protein synthesis of M. tuberculosis and therefore target actively 
dividing bacilli. KAN, AMK and CAP bind to ribosomes of M. tuberculosis and prevent elongation of 
the peptide chain during protein synthesis. Resistance to KAN and AMK is associated with mutations 




aminoglycosides have been observed where CAP becomes more valuable. Resistance to capreomycin 
has been associated with a mutation in the gene tlyA encoding 2’-O-methyltransferase, an enzyme 
involved in addition of methyl groups to rRNA of 16S. However, some studies have reported 
capreomycin resistant isolates lacking mutations in the  tlyA gene 83. 
Fluoroquinolones (FQ) 
Fluoroquinolones are synthetic antibiotics with a broad spectrum of activity, commonly used in 
treatment of various bacterial infections for instance in the gastrointestinal, respiratory and urinary 
tract. They have shown excellent activity against M. tuberculosis both in vitro and in vivo. 
Fluoroquinolones drugs that have been used to treat multi-drug resistant TB are ofloxacin, 
moxifloxacin, levofloxacin and gatifloxacin. Ciprofloxacin was recently found to have a weaker 
efficacy against TB compared to its counterparts and is no longer recommended as part of TB 
treatment 84. Severe side effects from some fluoroquinolones which may result in sudden death have 
impelled the World Health Organisation to recommend that only levofloxacin and moxifloxacin 
which have high potency and fewer side effects be used to treat MDR-TB patients 84. 
Fluoroquinolones inhibit bacterial DNA gyrase thereby preventing DNA replication. 
DNA gyrase is a topoisomerase which consists of two sub units A and B, encoded by gyrA and gyrB, 
respectively. Most FQ resistance occurs from M. tuberculosis strains with mutations in a small region 
of gyrA gene called the quinolone resistance determining region (QRDR) and less frequently in gyrB 
gene. 
Thioamides  
Thioamides consist of ethioamide and prothioamides which are derivatives of isonicotinic acid as is 
INH. Thioamides are pro-drugs that require activation by mycobacteria upon cell entry. Although 
ethioamide have structural similarities to INH and a similar target which is the  inhibition of InhA in 
order to halt cell wall synthesis,  they seem to have a different activator, flavin monooxygenase 
encoded by ethA gene 85,86. Thioamides have similar efficacy against M. tuberculosis and they can be 
used interchangeably. Mutations in EthA gene and InhA were found in ethioamide  resistant clinical 
isolates 87. 
P-aminosalicyclic acid (PAS) 
P-aminosalicyclic acid is one of the first anti-TB drugs, discovered in 1944. As old as it has been, its 
mechanism of action is still unknown. Recent studies have shown that PAS is a pro-drug that is 
activated to its active metabolite by an unknown enzyme. Activated PAS then targets dihydrofolate 
synthase, a key enzyme in folate synthesis. Overexpression of drfA gene confers PAS-resistance in M. 





D-cycloserine is a key antibiotic currently used in second-line treatment for extensively drug resistant 
TB. Cycloserine is a structural analogue of an amino acid D-alanine which can be found in bacterial 
cell walls. It acts as a competitive inhibitor of alanine:alanine ligase, an enzyme that combines alanine 
amino acids into an alanylalanine peptide, an important component in peptidoglycan synthesis and 
thereby interrupting mycobacterial cell wall formation 89. The key advantage of cycloserine is the 
absence of cross resistance with other drugs. Overexpression of alanine racemase and alanine:alanine 
ligase, enzymes involved in alanine metabolism and peptidoglycan biosynthesis respectively result in 
D-cycloserine resistance 90. 
Group 5 anti-TB drugs 
These drugs are not yet well studied for use in drug resistant TB, but may only be used to support 
regimens for patients with MDR-TB or XDR-TB that are resistant to other routinely drugs. 
Amoxicillin/clavulanate 
Amoxicillin/clavulanate is a β-lactam antibiotic. β-lactams antibiotics were initially developed to treat 
infection caused by gram-positive bacteria in 1940s. β-lactams targets the cell wall synthesis by 
binding to the transpeptidases which catalyzes peptidoglycan cross linking 91. Although the broad 
spectrum of β-lactamase activity in M. tuberculosis limits the antibiotics potential of B-lactam in TB 
treatment, addition of clavulanate have shown to inhibit b-lactamase activity thereby enhancing B-
lactam activity 92. The combination of B-lactam and B-lactamase result in increased efficacy against 
TB for instance in amoxicillin/clavulanate. Amoxicillin/clavulanate is an antibiotic used as a last 
resort in drug resistant TB treatment due to its unclear efficacy and safety. Although it is inexpensive, 
amoxicillin/clavulanate has been subjected to quality concerns and its interaction with TB and HIV 
medication is still unclear. 
Bedaquiline (BDQ) 
Bedaquiline also known as diarylquinoline or TMC207 was approved by the Food and Drug 
Administration (FDA) in late 2012 for treatment of drug resistant TB. This compound shown high 
activity against both sensitive and resistant strains of mycobacteria 93. This was the first time in over 
40 years that this agency had approved a new TB drug with a different mode of action. Bedaquiline is 
a first in the new class of drugs aimed to treat the drug resistant strain of TB. Bedaquiline targets 
mycobacterial ATP synthase, a critical enzyme in ATP synthesis of M. tuberculosis. Binding of 
bedaquiline to the oligomeric and proteolipid subunit-c of mycobacterial ATP synthase leads to 
inhibition of ATP synthesis, which later result in bacterial death. It is effective against replicating and 




remains questionable, given the potential risks including serious side effects, elevated risk of death, 
demonstrated in a phase II trial, where about 11.4% of patients taking bedaquiline died during clinical 
trials compared with 2.5% of those taking placebos. As the drug carries some significant risks, it is 
mandated to be used only in patients who do not have other treatment options 94.  
Clofazimine (CFZ) 
Clofazimine is a lipophilic riminophenazine antibiotic that was primarily used for treatment of 
multibacillary leprosy in 1962. Clofazimine was shown to be active against M. tuberculosis in vitro 
including MDR-TB strains, it was however considered ineffective in treatment of pulmonary TB. 
Early studies demonstrated inconsistent therapeutic activity of clofazimine in various animal models 
including rabbits and guinea pigs. Over the years with the emergence of MDR-TB and XDT-TB, a 
renewed interest in clofazimine as an anti-TB drug was triggered. Even though it has been 
recommended for use in patients with drug resistant TB, it is not approved or well-studied for 
treatment of TB. Clofazimine is recommended for use in combination with other drugs in the second-
line treatment of drug resistant TB. Pigmentation of skin to reddish-brown in colour is one of the 
unpleasant side effects which gradually subsides upon treatment cessation 95. 
Delamanid 
Delamanid is a novel drug that was approved by European Medicines Agency late in 2013 for the 
treatment of drug resistant TB on condition that it is used as part of an appropriate combination 
regimen in adult patients whose currently approved regimen cannot be used due to resistance or 
intolerability. However, delamanid is not yet widely available for patients outside the European Union 
or clinical trials. Delamanis is a dihydro-nitroimidaoxazole derivative and a pro-drug that is activated 
by a mycobacterial enzyme, deazoflavin dependent nitroreductase to its active metabolite that plays a 
role in the inhibition of the mycolic acid synthesis. Studies have shown that delamanid has high 
potency, least risks of drug-drug interaction with antiretroviral drugs which makes it an important 
option in treating drug resistance in patients infected with HIV 96,97. 
Linezolid 
Linezolid is an antibiotic used in drug-resistant treatment when limited options exist. Although not 
approved for TB treatment, linezolid demonstrated high efficacy against XDR-TB on clinical trials. 
However it is often not given to patients with XDR-TB due to its lack of availability and prohibitive 
cost 97. Linezolid had been shown to cause severe side effects including 
anaemia/thrombocytopeniaa lack of blood platelets which causes slow blood clotting after injury 
which may result in constant bleeding. Despite these severe side effects, studies have reported cures 




Linezolid falls within a group of compounds called oxazolidinones which bind to the 50S subunit of 
the prokaryotic ribosome, preventing the binding of 30S subunit to form a complex with mRNA 
initiation factor and formylmethionyl-tRNA, blocking the assembly of a functional initiation complex 
for protein synthesis preventing mRNA translation. The advantage that comes with incorporation of 
linezolid in drug resistant treatment regimen, is that this drug has a unique target that does not overlap 
with existing drugs 98. 
1.3 Currently Available TB Diagnostics and Drug Susceptibility Testing Tools  
Diagnosis of tuberculosis is confirmed by identification acid-fast bacilli by smear or by isolation of 
M. tuberculosis in cultures or identification of its genomic material by molecular tests. 
Drug resistant tests are not routinely carried out in most cases and it is only after treatment failure that 
drug resistant tests are performed 99. This fuels the spread of drug resistance which is difficult to 
manage. Focussing on rapid and easily accessible diagnostics and drug susceptibility testing is of 
paramount importance to enable early detection and prescription of appropriate anti-TB drugs. This is 
bound to minimize the spread of TB and drug resistant TB strains. XDR-TB is currently associated 
with high mortality rate and therefore posing a major challenge that threatens public health. 
1.3.1 Miscellaneous Tests 
1.3.1.1 Sputum Smear Microscopy 
Sputum smear microscopy is primarily the mostly used method for diagnosis of pulmonary TB 
predominantly in low and middle income countries 100. Two techniques are used for TB diagnostics 
with sputum smear microscopy; fluorescent microscopy which uses acid-fast fluorochrome dye 
(auramine –rhodamine) and conventional microscopy uses carbol fuchsin Zeihl-Nelsen (ZN) or 
Kinyuon staining. Zeihl-Nelsen staining is a widely used technique for the identification of acid-fast 
bacilli. In this process a thin smear of the sputum specimen is deposited on a glass slide, exposed to 
hot carbol fuchsin dye for 3 minutes, rinsed, decolourized with a dilute acid-alcohol solution and 
stained with methylene blue solution and rinsed with water. Mycobacteria absorb the carbol fuchsin 
dye but withstand decolourization by the acid-alcohol, as a result of the high lipid content in their cell 
walls which explains the name acid-fast bacilli 101. The conventional light microscope is then used, 
where the bacilli appear dark red to dark purple against the blue background.  When the sputum is 
stained with fluorochrome dye rhodamine-auramine stain in which case a fluorescent microscope is 
used, the bacilli fluoresces yellow to white against the dark background. Auramine is more sensitive 
than Ziehl-Nelsen stain but less specific and more expensive 101,102.  
Sputum smear microscopy is useful in low income settings which are highly burdened by TB, because 
it is rapid, simple to perform and cost effective 102. In areas with very high TB prevalence, sputum 




loadthe number of bacilli in the smear and the probability of their being identified by microscopy 
103. The sputum microscope results are reported and graded according to each patients’ bacillary 
concentration reflecting the extent of lesion in a particular patient which is directly proportional to the 
infectiousness of the case (Table 2). Although this technique is the most widely used rapid diagnostic 
test, it has some limitations. The threshold of detection is immensely compromised when the bacterial 
load is less than 10000 organisms per mL sputum sample. This explains the sensitivity of 60% which 
drops drastically in paediatric TB and patients co-infected with HIV and TB to 30%. 
Table 2: Grading of AFB smear as per WHO recommendation 
No. of acid-fast bacilli (AFB) Fields Report  
No AFB In 100 immersion fields Negative  
1-9 AFB In 100 immersion fields Positive scanty (report exact number) 
10-99 AFB In 100 immersion fields 1+ positive 
1-10 AFB Per fields (examine 50 fields) 2+ positive 
More than 10 AFB Per fields (examine 20 fields) 3+ positive 
 
Limited resources and large number of samples, all combined together often reduce the observation 
time per slide to less than 60 seconds which contributes to the reduction of sensitivity of the test 100. 
Sputum microscopy cannot distinguish between dead, alive bacilli or and mycobacterial species and 
cannot differentiate between drug susceptible and resistant strains. Overall, sputum smear microscopy 
still plays a pivotal role in resource limited communities and high TB burdened area until a more 
reliable, affordable and fast diagnostic test is available, until then, sputum microscopy seems to be 
here to stay. 
1.3.1.2 Chest X-ray 
Chest radiography is often used for evaluation where there is compatible symptoms but negative 
laboratory tests results 102. Chest X-ray assists a clinician to determine the presence of TB in the lung 
in a form of lesion. Patients with active TB  often have upper lobe cavitary infiltrates 101. However, an 
X-ray might present some abnormalities in lower or mid-lung field in TB patients. However, there 
have been instances where a chest X-ray may appear normal even in the case of TB infection; this is 
often observed in patients co-infected with HIV and TB. Poor film quality and non-expert readers 
have been reported to compromise this test 104. 
1.3.2 Phenotypic Methods 
1.3.2.1 Culture Based Method  
Conventional culture methods for drug susceptibility testing (DST) are based on inoculation of M. 




used as a standard technology and is still being used in many countries worldwide. The standard 
method using egg-based Lowenstein-Jensen (LJ) medium includes the proportional method, the 
absolute concentration method and the resistance ratio method which have been well standardized 
with clinical samples. Substantial amount of data from many countries report the proportional method 
to be the most commonly used 105. The proportional method enables a precise estimation of the 
proportion of M. tuberculosis mutant strains resistant to a given anti-TB drug. This is determined by 
comparing quantity of growth in a drug-containing and drug-free control medium from countable 
colonies (50-100). The proportion of bacilli resistant to a given drug is expressed as the resistant 
portion of a percentage of the total population used. If over 1% of M. tuberculosis mutant population 
can grow the strain is rendered resistant 106,107. 
The absolute method uses a standardized inoculum grown in drug-containing media and drug-free 
media. Several concentrations of each drug are tested, and resistance is expressed in terms of the 
lowest concentration of drug that inhibits growth called minimal inhibitory concentration (MIC). This 
method is greatly affected by the initial number of organisms 107,108. 
The resistance ratio method compares growth of the unknown tubercle bacilli strains with the drug 
susceptible standard laboratory reference strain (H37Rv) in the same set of tests. Resistance is 
expressed as the ratio of the MIC of the test strain divided by the MIC of the standard strain. An 
isolate with a ratio of eight or more is considered resistant to the given drug 107,108. 
When performed on egg-based media, the final results’ reading is done after 42 days of incubation. 
When agar-based media is used, results are obtained after 21 days of incubation. This delay is 
additional to the time required to first grow isolates in drug free medium from sputum sample in case 
an indirect method is used which can take 3 weeks. In contrast to the indirect method, is the direct 
method where the concentrated sputum specimen is directly inoculated to a set of drugs containing 
and drug-free media. The direct method has more advantage in that the results become available 
sooner and better represent the patient’s original bacterial population. However, this is determined by 
the initial bacterial load from the sputum sample 108,109.  
Conventional culture method remains the gold standard because it has been standardised for DST of 
many drugs, require no specialised equipment, inexpensive and more reliable than the sputum smear 
microscopy. The greatest limitation of the conventional culture tests is the long turnaround time, with 
3 weeks to a month of incubation until the results can be obtained. Meanwhile the patient needs to 
start their drug treatment. In addition, when using egg-based media, a large number of tubes are 
inoculated for each test and incubated for 42 days, requiring large amount of incubator space. Careful 
quality control of all batches produced with drug susceptible or resistant for reliable results is of 




New phenotypic methods have been developed aimed at rapid detection of growth using metabolic 
activities of dividing mycobacteria to determine mycobacterial growth and drug susceptibility. More 
recent methods include BACTEC MGIT-960 TB system which is based on liquid medium. MGIT is 
an automated, continuously monitoring system based on fluorometric technology for detection of 
oxygen consumption by bacteria growing inside the MGIT tubes. Each MGIT tube contains a 
fluorescent sensor which is oxygen quenched, embedded at the bottom of the tube. The consumption 
of oxygen by growing mycobacteria causes the fluorochrome to fluoresce under UV light. DSTs are 
performed on prepared kits of anti-TB drugs, mycobacteria are then inoculated on two tubes, one 
containing the testing drug. Detection of fluorescence in drug-containing tubes determines that a 
given strain is resistant. The test is completed within 10 days 110.  
The limitation of the MGIT is the richness of medium used where non-mycobacterial species and 
other fast growing mycobacteria can overgrow present M. tuberculosis and therefore yield false 
positive results. This system is too expensive for laboratories in resource limited settings due to the 
cost associated with acquiring of MGIT-960 system components, the price list are $63,900 for the 960 
instrument, $824 for a carton of 100 culture tubes and $92.70 for the supplement kits (100 tests, 
growth and antibiotics supplements) 111. 
1.3.2.2 Phage-based Test 
The use of bacteriophage for bacterial detection was first reported over a century ago where an assay 
to detect Salmonella using phage Felix 01 was described in 1954. Mycobacteriophage are phage that 
infect species of the mycobacterium genus. Over 200 different mycobacteriophage have been 
described infecting a broad range of mycobacterial hosts isolated from soil, surface water, stool and 
resection specimens of patients with TB or sarcoidors 112,113. 
The FASTplaque TB (Biotec, Ipswich, Suffolk, UK) is the only commercially available phage-based 
kits for detection of mycobacteria on the market. FASTplaqueTB is a phage amplification assay 
which detect the presence of mycobacteria by the formation of plaques at the end of the assay and 
offers a phenotypic test with a turnaround time of 4 days 114. 
Initially the samples containing the target cell is mixed with a high titre of the bacteriophage. The 
samples are then incubated to allow time for cell infection to occur and for phage to enter the cell, at 
this point any exogeneous phage that did not enter the appropriate host cells are destroyed by the 
addition of a virucide. A virucide is a chemical that inactivates the phage but have no effect on the 
viability of the host cells. The internalised phage is then detected when the progeny get released at the 
end of the lytic cycle by the formation of plaques (the area of no growth) in a bacterial lawn. The 
FASTplaqueTB uses a D29 mycobacteria phage with a broad host range and can also infect fast 
growing, non-pathogenic M. smegmatis used as a fast growing host to produce lawns of bacteria to 




as FASTplaqueResponse which can be used on direct patient sample or indirect isolates. In this assay 
phage growth is inhibited in the presence of the antibiotic 115.  
This assay is simple to perform, affordable and require no expensive equipment. However, it does 
require a functional microbiology laboratory and cannot be used in remote areas. The specificity of 
this assay is an issue since the test utilizes a broad host range phage D29 to allow slow growing and 
fast growing mycobacteria to be infected. In addition the test is reported cumbersome with high 
variability. This makes it difficult to determine whether the cell detected is TB or non-tuberculous and 
therefore resulting in false positive results, without the use of an additional test such as PCR 
amplification to confirm signature sequence or culture methods 116. 
1.3.3 Genotypic Methods 
Genotypic methods are DNA based assays that targets characterised resistant associated mutations to 
identify drug resistance in M. tuberculosis. Mutations conferring drug resistance have been described 
for most first line and second line anti-TB drugs. There are number of genotypic assays that have been 
developed and available for the detection of resistance determining mutations in M. tuberculosis.  
1.3.3.1 Line Probe Assay (LPA) 
In 2008, the World Health Organization authorized the use of line probe assays for the rapid detection 
of MDR-TB. Line probe assay involves DNA extraction, amplification of a predefined gene region 
associated with resistance, and reverse hybridization of the PCR products with standard immobilized 
probes for gene mutations associated with resistance 117. At present there are three commercially 
available line probe assays for the detection of first-line drug resistance of M. tuberculosis. While 
rpoB gene mutations responsible for rifampicin resistance are detected by all three assays; the INNO-
LipA (Innogenetics, Belgium) detects RIF resistant mutation in the rpoB region only, Genotype 
MTBDR  additionally detects KatG mutations, and second-generation Genotype MTBDRplus (Hain 
LifeScience GmbH, Germany) detects mutations conferring resistance in rpoB, katG and inhA genes 
118.  
Hain Lifesciences released the GenoType MTBDRsl test in 2009, designed to test for resistance to 
second-line anti-TB drugs (fluoroquinolones, ethambutol, aminoglycosides and cyclic peptides), 
which can be used in combination with the MTBDRplus test to identify XDR-TB. The major 
advantage of LPA is that they can be performed directly on smear-positive sputum samples, giving 
rapid (approximately 5 h) drug susceptibility results without the need for culture. Many laboratories 
are now using LPAs as the primary method for DST on cultured isolates of M. tuberculosis, replacing 
phenotypic DST. The disadvantages of LPAs are that they are labour intensive, still limited to 
detection of resistance caused by known mutations; require highly trained personnel and dedicated 




1.3.3.2 Gene Expert 
In 2010, the World Health Organization authorized the use of GeneXpert MTB/Rif TB assay 
(Cepheid, CA) as the initial diagnostic test for TB in individuals that are suspected of MDR-TB or 
HIV-TB co-infection. GeneXpert uses real-time PCR with molecular beacons, probes for 
hybridization to different target segments within a region of the gene of interest. When nucleotide 
concordance between the probe and target of interest matches, the beacon emits fluorescent signals. 
The absence of a signalling suggests a mutation in the target segment region 119.  
The GeneXpert machine is a fully automated closed system that performs both sample preparation 
and real-time PCR, producing results in less than 2 hours. GeneXpert is capable of detecting the 
mycobacterium tuberculosis complex (MTBC) while simultaneously detecting RIF resistance by 
targeting the RRDR of the rpoB gene. Analytical sensitivity and specificity was 100 % according to a 
study using RIF resistant and sensitive M. tuberculosis isolates and non-tuberculosis bacteria 120. The 
assay is designed for direct genotypic DST from unprocessed sputum or sediment from a concentrated 
specimen. Sample reagent is poured into the tube, incubated for 15 min and pipetted into Xpert 
machine for processing.  
Major advantages of the Xpert machine is rapid turnaround time of less than 2 hours, hands-free 
processing, therefore no highly trained staff is required to run the machine or interpret the results, 
near-patient technology and high throughput 121,122. The major limitations include the cost of 
equipment, the price for GeneXpert machine is approximately US$ 17 000 and the Xpert MTB/RIF 
tests cost approximately US$ 17 per cartridge which is quite costly 123.  It only can be used in 
equipped laboratories, and unlikely to be used in rural health centres, due to poor infrastructure and 
limited resources. GeneXpert is also limited to only detect drug resistance of one drug, rifampicin, it 
cannot detect resistance-incurring mutations outside of specified target region, and the detection of 
silent mutations which are falsely interpreted as conferring resistance. However, some studies have 
reported that most isolates resistant to RIF are also resistant to INH in about 90% of the time, 
suggesting that the presence of rpoB mutation can be used as a surrogate marker for MDR-TB. 
1.3.3.3 DNA Sequencing 
DNA sequencing is considered the gold standard with the capacity to both identify M. tuberculosis 
isolates and evaluate for drug resistance. Conventional DNA sequencing utilizes a chain-termination 
method to sequence DNA fragments. It first binds a primer to a denatured single stranded DNA 
followed by DNA extension which begins at the primer site using DNA polymerase. This is 
terminated because a dye-labelled dideoxynucleotide interrupts phosphodiester bond between two 
subsequent nucleotides. This cycle results in DNA fragments of various lengths, which can be 
separated by electrophoresis and subsequently sequence. The limitations in using this highly accurate 




also highly burdened with TB. In addition, a highly trained personnel is required for results 
interpretation. 
There is a pressing need for a phenotypic test that can produce results with the speed and reliability of 
the best nucleic acid test but without the limitation of the specific already known DNA sequence 
mutations that confers drug resistance. 
1.4 Phenotypic and Genotypic DST  
Traditionally, phenotypic drug susceptibility is determined by either broth or agar dilution which rely 
on evaluation of bacterial growth in the presence of various concentration of antibiotic. This method 
allows for determination of MIC of the antibiotic, a lowest concentration that prevents bacterial 
growth. These tests take long (weeks to months) in slow growing mycobacteria such as M. 
tuberculosis. This may have serious implications; the patient may spread active drug resistant TB 
endangering many lives whilst waiting to start appropriate treatment. 
While various genotypic markers have been identified for drug resistant TB strains, phenotypic 
methods still predominates genotypic detection methods for antibiotic resistant gene. Measurements 
of bacterial phenotypic response to antibiotics remains gold standard due to diverse resistance 
mechanisms and continuous evolution of pathogenic bacteria. The genotypic methods are useful for 
screening, but may fail in case a newly acquired drug resistance is independent of target gene 
expression. Gene Xpert for instance is not only expensive, it is also limited to detecting mutations that 
confer resistance to rifampicin from a predefined region. Genotypic methods are still limited when it 
comes to detecting epigenetic mechanism that may result in drug tolerance for instance efflux 
mediated drug tolerance. Efflux pumps are membrane proteins that can extrude a variety of toxic 
agents such as antimicrobials and chemotherapeutic agents. Substantial proportion of drug-resistant 
isolates have no identifiable mutations in known resistance associated genes, and it appears that 
resistance in some of these isolates may result from increased efflux activity. Multiple studies have 
reported increased efflux pump expression in M. tuberculosis clinical isolates. This phenomenon may 
have serious clinical implication such as prescription of the standard TB regimen to patients with 
unrecognizable drug-resistant TB. This is likely to happen in areas where access to mycobacterial 
culture are limited. As a result culture-based drug susceptibility test methods remain the gold standard 
in clinical microbiology laboratories. Current conventional phenotypic methods employed for drug 
susceptibility testing have a slow turnaround time as they require long incubation hours and bulky 
supporting instrumentation. An ideal test would be phenotypic so as to be robust to genetic variations 
and applicable to emerging disease evolution, while also delivering antibiotic susceptibility 







2.1 Introduction to Microfluidics 
Since its inception in the early 90s, microfluidics technology has undergone tremendous progress. 
Microfluidics technology is the science of systems that deals with the flow of liquids in micro-sized 
channels 124. The microfluidics technology involves designing and manufacturing devices with size 
dimensions ranging from micrometres to millimetres. A microfluidic device contains a set of micro-
channels engraved into materials such as silicon, glass or polymer.  These devices enable 
manipulating fluids in picoliter to microliter volumes in channels with dimensions of tens of 
micrometres. In a microfluidic chip, the micro-channels serve to achieve a specific function such as 
mixing, pumping, flowing liquids inside the channels. These micro-channels are connected to the 
outside by input- and output ports incorporated into a microfluidic chip to allow introduction and 
removal of fluids and reagents from the chip with external systems such as pressure controller or push 
syringes. 
Different substrate materials have been used for fabrication of microfluidics devices, such as ceramic, 
Teflon, steel and silicon. The fabrication methods for these different platforms may vary due to the 
differences in properties of the substrates. Most fabrication processes are based on photolithography, 
initially developed in IC (integrated circuit) technology. Although silicon is now rarely being used as 
a substrate for microfluidic devices due to its complicated and costly fabrication process, in the early 
developmental days of microfluidics technology, silicon was a widely used substrate material for 
fabricating microfluidics devices for various applications. Silicon contributed vastly to the rapid 
evolution of microfluidic technology. The fabrication process for silicon-based devices involved 
lengthy processes such as substrate cleaning, photolithography, metal deposition and wet/dry etching. 
Moreover, the silicon substrate is relatively expensive and optically opaque therefore limited in 
optical detection. To overcome these short comings, silicon was later replaced with glass and 
polymeric materials which on the other hand were less expensive and optically transparent. Polymer 
materials including polymethacrylate (PMMA), polystyrene (PS), polycarbonate (PC), and 
polydimethylsiloxane (PDMS) were then adopted. Due to their low cost, ease of fabrication and 
physical properties, polymers are now the primary materials used in microfluidic research.  
 
The most widely used polymer in fabrication of microfluidic devices is Poly Dimethyl Siloxane 
(PDMS), an optically transparent, soft elastomer. PDMS has numerous advantages such as 
biocompatibility, flexibility in moulding, elasticity and simpler fabrication process (soft lithography). 




PDMS substrate. Microfluidic chip fabrication using PDMS is a relatively simple process that require 
a special facility called the cleanroom. This process allows rapid building of prototype followed by 
testing their application in minimal time frames. The microfluidic chips uses miniaturised micro-
chemical membrane valves also made up of PDMS which efficiently control the movement of fluids 
within the channels. Multi-layer bonding of PDMS, microfluidic actuators including on-off valves, 
switching valves and pumps can be fabricated on-chip. To achieve this, the polymer membrane in 
between the channels is engineered to be relatively thin—for instance 30 µm. Once the pressure is 
applied to the upper channel, the membrane deflects downward and closes the lower channel 125,126. 
The valves also allow creation of multiple channels which can be used to form different 
compartments. This process is simple, and the microfluidics device is completed within few hours. 
 
Microfluidics technology is currently explored by various fields and has found many applications in 
the biomedical field, biological applications and drug screening in pharmaceutical industries such as 
gene/protein manipulation and analysis, cell-based systems, biosensors and drug discovery and 
delivery. Some studies have created microfluidic devices for nucleic acid purification,  where a single 
chip was used to sequentially process nanoliter volumes to isolate variable number of bacterial and 
mammalian cells, lyse them and purify their DNA and mRNA without pre and post sample 
preparation 127. Recent development advances in microfluidic technologies have also miniaturized the 
flow cytometer to perform simple, rapid and affordable CD4 T-lymphocytes counts especially for 
HIV. In a different study Kitamori developed a micro-ELISA system for rapid and sensitive 
diagnosis. The permeability of polymer to gases makes it suitable for work with living cells 128. 
The microfluidics technology has a number of features suitable for cell-based assays: the micro-scale 
dimension mimicking the microstructure and native environment of the in vivo systems; it requires 
small samples therefore low reagent consumption. The polymer used such as polydimethylsiloxane is 
permeable to oxygen and the microfluidics technology can combine multiple steps such as cell 
culture, cell sampling, fluidic control, cell lysis, mixing and detection on a single device. 
Pathogenic bacteria normally reside in microstructures within human tissues. In order for 
conventional culture methods to detect bacteria they require small number of bacteria growing into a 
colony forming unit which usually takes days to months. Advances in microfluidics technology have 
allowed the use of microfluidic devices to trap and immobilize bacterial cells within micro-channels 
without altering the cell properties whilst simultaneously exchanging media and observing cell 
behaviour in real time. 
The recent developments of transparent microfluidic devices have enabled long term cell culturing. A 
number of studies have developed microfluidic devices for bacterial cell growth and one particular 




different study by Balagadde et al., a microchemostat bioreactor enabled long-term culture monitoring 
using E.coli 129. Recently, Aldridge et al. used a microfluidic device to demonstrate differences in 
elongation rate and size within a clonal population of mycobacteria, and established that the resulting 
sub-populations of cells are differentially susceptible to antibiotics 130. 
2.2 Benefits of Microfluidics  
Microfluidics has the potential to transform management of clinical diseases and the development of 
new diagnostics at the point of care, for rapid drug susceptibility testing.  Developing culture-based 
drug susceptibility tests using microfluidics has numerous advantages such as effective sample usage 
since it requires small sample and reagent quantities, high detection sensitivity, and reduced analysis 
times. At the same time microfluidic devices are easily scalable to perform multiple tests on multiple 
samples. The large surface to volume ratio of PDMS microfluidic systems enables the rapid detection 
of the bacterial growth 131. Direct observation of bacteria dividing from one to two cells allows faster 
detection of the effect of antimicrobial agents on bacterial growth. Sufficient concentration of oxygen 
is also required for rapid growth of mycobacteria in microenvironments. High surface to volume ratio 
of microfluidic micro channels allows abundant oxygen in micro channels. This approach has the 
potential to shorten the waiting time for DST results, which in turn may encourage prescription of the 
most appropriate medication to patients and allow patient personalised medicine and treatment. This 
can reduce the risk of the emergence of drug resistant TB strains.   
2.3 Statement of Problem 
The emergence of drug resistant TB is becoming a major threat to global health. Drug resistant TB 
keeps advancing as a result of inappropriate use of anti-TB multi-drug chemotherapy. Physician errors 
such as improper drug administration and patients’ poor compliance are among the major  
contributing factors to drug resistant TB 132. Reports have continually showed lower number of drug 
resistant TB among newly diagnosed cases 2.3%, relative to higher proportion of MDR-TB from 
retreatment cases 71.4%, suggesting improper use of anti-TB drugs. In South Africa approximately 
1.8% new TB cases and 6.7% treated cases are multi-drug resistant 74. Studies have shown that the 
majority of new drug resistant TB (DR-TB) cases diagnosed in SA are due to transmission of already 
resistant strains 133. Limited access to reliable diagnostic tools is one of the hurdles South Africa has 
to overcome. To combat this dilemma rapid and reliable drug susceptibility testing tools are required 
for guidance of treatment and surveillance of drug resistance. Early detection of the bacilli will 
prevent further spread of drug resistant TB strains in the communities and prevent administration of 
inappropriate treatment regimen. Microfluidics provides a platform with the potential to produce high 




2.4 Knowledge Gaps 
After reviewing the literature, it was evident that although DST tests are currently being performed, 
they still occur at a smaller scale and are cumbersome thereby making it difficult to be outsourced or 
available to every patient in need of these tools. Cheaper diagnostic tools seem to be cumbersome and 
take time for results to be available for instance culture methods. As a result these methods are good 
at detecting resistance but are not efficient. Genotypic methods are fast at detecting resistance 
however not everyone can afford them and they are also more dependent of already known mutations 
that cause drug resistance. With that being said these tools might miss drug resistance in case it is 
presented by an unknown mutation. Therefore an ideal drug susceptibility tool is that which produces 
fast, accurate result in less time possible. A search of existing literature does not yield any evidence 
for microfluidics applications for DST in clinical TB practice. However, the literature reveals 
promising microfluidics devices aimed at development of diagnostic tools that yields highly accurate 
drug susceptibility results for multiple anti-tuberculosis antibiotics 134,135. 
2.5 A Microfluidics Chip for Culturing Tuberculosis 
This project was aimed at developing a culture-based drug susceptibility test for tuberculosis using 
microfluidics that is reliable and fast with less human involvement. 
2.6 Objectives  
1. To create a microfluidic chip that will grow mycobacterial cells and expose them to different 
antimicrobial agents. 
2. To create a chip that will perform drug susceptibility tests whilst mimicking the 
microenvironment in terms of size similar to mycobacteria growing inside the membrane 
bound compartment of a macrophage. 
3. To create a drug susceptibility test that can distinguish between bacteriostatic and bactericidal 
antimicrobial agent. 
2.7 Brief Thesis Overview  
The aim of this project was to develop a drug susceptibility test using microfluidics. We designed and 
fabricated the microdialyser chip. Chapter 1 consists of the literature review. Chapter 2 describes the 
microdialyser chip design and fabrication according to Microfluidics Large Scale Integration (MLSI). 
Initially the motivation of this design of the microdialyser design is explained and therefore the reason 
for the modifications of the microdialyser chip design. Chapter 3 shows how we validated the 
functionality of the microdialyser units using calorimetric assays. We then used the microdialyser 
units to culture mycobacteria under different growth conditions. This was followed by treating 
mycobacterial cells with a series of antibiotics where we observed epigenetic drug tolerance which led 
us to modify the microdialyser chip by introducing bioreactors with variable sizes. We also describe 




growing in a space confined environment which was found to be efflux mediated. Chapter 4 consists 
of the concluding remarks of this thesis. 
2.8 The Microdialyser Chip 
2.8.1 Introduction 
Mycobacterium tuberculosis resides intracellularly, inside the membrane bound compartment of 
macrophages within ~5 pL volume. Mycobacteria growing inside macrophages have been reported to 
be more resistant to antibiotics compared to mycobacteria growing extracellularly in liquid medium. 
In particular, the study conducted by Hartkoorn et al found that a higher concentration of rifampicin 
was required to kill intracellular bacilli (148 ng/ml) compared to extracellular bacilli (1.27 ng/ml) 136. 
In a different study by Adams et al they revealed that mycobacterial cells exposed to macrophages for 
96 hours became more tolerant to antibiotics (more than 200 fold for isoniazid, 20.6 fold for 
rifampicin and 4.8 fold for moxifloxacin  compared to those exposed to macrophages for only 2 
hours) 137. To mimic the size of the membrane bound compartment of macrophages we designed a 
microdialyser chip with miniaturized reactor volume of 200 pL. 
The main objective of this project was to develop a microfluidic-based platform that will grow M. 
tuberculosis isolates in multiple reactors and perform drug susceptibility tests with reduced human 
involvement. The drug susceptibility testing assay would include trapping growing microbes in 
microfluidic reactors and perform drug susceptibility screening for rapid measurements. Trapped 
mycobacteria would be exposed to different drugs or drug combinations at different concentrations to 
test for drug resistance and also find most effective drug combinations for each isolate. The growth 
rate was documented using automated optical micrography. 
With further research and development, this platform could be developed for investigating hundreds 
of patient sputum samples at the same time, which would minimize human contact with potentially 
infectious doses of M. tuberculosis. This approach could also be used to screen potential multiple drug 
compound combination mixtures for determining the most effective drug combination suitable for 
each specific TB patient. The availability of such a high throughput MTB drug resistance diagnostic 
and monitoring option could dramatically improve patients’ outcomes by preventing clinical disease 
progression and the transmission of drug resistant TB. This approach would be particularly more 
affordable in hospitals and medical centres where a high demand for microscopic observation drug 
susceptibility (MODS) testing also requires highly trained personnel to spend a considerable amount 
of time on each patient sample. 
2.8.2 Design and Fabrication 
Using the microfluidic plumbing technology of pneumatically activated Quake valves, mixers and 
pumps developed previously, we created a miniaturized, culture-based drug susceptibility testing on a 




(General Electric RTV 615) using multi-layer soft lithography described in the supporting 
information. The chip can support up to 120 microdialyser units that can run in parallel on each chip. 
 
Figure 9: A microdialyser chip with 120 microdialyser units that operate independently. Various 
inputs have been loaded with food dyes to visualize channels and other subelements of the chip, the 
tubes filled with red dye shows the 71 control lines. The coin is 10 mm in diameter. 
 
The microdialyser device was designed to trap approximately 5-10 mycobacterial cells in each 
microfluidic compartment and periodically expose these cells to different drug cocktails. This device 
consists of four identical modules (figure 11). Each module consists of 8 input ports for different drug 
stock solutions and a formulator ring for combinatorial drug mixing. The formulator is a fluidic loop 
that is 10 m high, 100 m wide and ~0.02 L volume, with an integrated peristaltic pump and a 
series of microchemical valves for injection of fluids into the ring and expulsion of fluids into 
designated reactors. There are 30 microdialyser units per module. Each microdialyser unit consists of 
two chambers: a micro-sized cell culture chamber or growth chamber that is ~200 pL in volume 
connected via a link valve to an adjacent conditioning chamber that stores fresh medium 800 pL 
(figure 1, chapter 3).  
 
To expel waste products such as used reagents and mycobacterial cell suspension the microdialyser 
has 15 output ports that operate as outlets. In order for the microdialyser chip to operate at its full 




microchemical valves have different operational duties including mixing of solutions, separation of 
fluids and trapping organisms in their respective channels. The microchemical valves can constrict 
and relax only when activated by the computer controlled control lines which can be pressurized― 
allows for closing and opening these microchemical valves. The microdialyser chip consists of 71 
control lines (figure 10). 
 
Figure 10: A schematic of the microdialyser chip design with 4 modules. The chip can support 
120 microdialyser units that operate independently. The reagents flow channels are shown in red and 
the control lines are illustrated by yellow and green lines. 
 
2.8.3 Characterization of Diffusive Mixing in a Micro-reactor of the Microdialyser 
To characterize the performance of the microdialyser chip we performed calorimetric assays using 
food dyes. The microdialyser would operate by trapping mycobacteria in miniaturized bioreactors 
where they will be exposed to different drug cocktails by passive diffusion between the conditioning 
chamber and the growth chamber. The microdialyser uses a microdialysis scheme to periodically 
introduce fresh nutrients and remove waste from a captive population of mycobacteria through 
diffusive exchange, mimicking the passive bi-directional exchange of pro and anti-mycobacterial 
factors across the macrophage membrane. The 200 pL mycobacterial growth chamber of the 
microdialyser is connected via a link valve to an adjacent chamber that stores fresh medium. 
Periodically, the link valve is opened for 60 seconds to allow small molecules to freely diffuse 
between the two chambers down their concentration gradient: fresh nutrients diffuse into the growth 
chamber while mycobacterial metabolic waste products diffuse into the conditioning chamber. The 
relative large size and non-motility deter the mycobacterial cells from exiting the growth chamber 
when the link valve is opened. Thereafter the conditioning chamber is filled with fresh medium and 
awaits the next microdialysis step. To investigate the time required for solution in the growth chamber 
to match that in the conditioning chamber, we calibrated the diffusive exchange functionality of the 




the concentration in the growth chamber to that of the conditioning chamber. We found that on 
average, the microdialyser replaced the growth chamber fluid within 6 microdialysis steps (figure 1, 
Chapter 3).  
 
2.8.4 Modification of Microdialyser Chip 
The microdialyser chip was modified later to allow various sized microdialyser units. In this design, 
all the components were kept the same such as the eight inputs port, 15 output ports, the formulator, 
the number of the control lines and the number of micro-sized reactors remained the same (reactor 
11A). However, only six 200pL volume reactors were kept, the rest of the 200pL microdialyser units 
were replaced by eight 1700pL growth chambers, eight 1200pL growth chambers and eight 500pL 
growth chambers (figure 11B). Colorimetric assays ascertained that diffusive mixing pattern of the 
microdialysis scheme was similar across all growth chamber sizes (figure 12). 
 
    
Figure 11: A modified microdialyser chip. A) A schematic of a modified microdialyser design 
showing one module. Illustrating maintained chip architecture with all other subelements in the 
modified chip kept the same as in the original design except variations in reactors sizes. B)  A 
pictogram illustrating different reactor sizes ranging from eight 1700 pL, 1200 pL, 500 pL and six 200 
pL volume growth chambers. Reactors were loaded with food dyes to visualize different reactor sizes. 
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Figure 12: Functional illustration of diffusive exchange in the multi-volume microdialyser 
showing the dye concentration in the various growth chamber volumes and the conditioning 
chamber. The formulation in the conditioning chambers is cycled between DYE (cycles 2-7 and 13-
19) and WATER (cycles 1; 8-12). The dye concentration in the various growth chambers is 
determined by the formulation in the conditioning chamber. The chamber-to-chamber variations in 
dye concentration are attributable to minor height differences in the growth chambers. 
During microscopic counting 6 images were captured for each 1700 pL and 1200 pL growth chamber, 
3 images for each 500 pL growth chamber and 1 for each 200 pL growth chamber to cover the whole 
surface area of each reactor. We then developed image-processing algorithms in Matlab to determine 
the number of cells in each reactor picture set, from which the total cell density was determined. This 
new microdialyser design has now an additional capability for investigations aimed at addressing 




2.9 Macrophage Membrane Biology 
Macrophages are mononuclear phagocytes which appear throughout the body, which can be found in 
high numbers in connective tissues, the submucosa of the intestinal tract, the lung, the liver, the spleen 
and along specific blood vessels. On their cell surface, macrophages express several cell-receptors, 




receptor, glucan receptor, bacterial lipids such as LPS receptors and structure typically found on 
pathogen surfaces such as Toll-like receptors.  
Macrophages engulf and kill invading microorganisms and are crucial for eliciting immune responses. 
They produce pro-inflammatory cytokines such as IL-1β and TNF-α. Tubercle bacilli are encountered 
and engulfed by alveolar macrophages, which reside in the lung.  
The binding of a bacterium to a macrophage receptor stimulates the engulfment of the pathogen into 
intra-macrophage vesicles, a process known as phagocytosis. Once the pathogen has been surrounded 
by the membrane of the phagocyte, it is then internalised into an intracellular vesicle called 
phagosome. The pH inside the phagosome is then lowered to foster destruction of the pathogen. In 
addition, phagosomes typically fuse with lysosomes―intra-macrophage organelles containing 
degradative enzymes enclosed in a membrane― which degrade the pathogen using lysozyme 
enzymes. Mycobacteria have been reported to withstand the harsh conditions encountered inside the 
macrophages (phagosomes) because of their thick cell wall. As a result, this has led to a manipulation 
of the host cells by mycobacteria for their own survival whereby mycobacterial cells replicate within 
the macrophage instead of dying. 
The macrophage is surrounded by a plasma membrane and in a simplified model, the macrophage can 
be considered to be a tiny growth chamber for mycobacteria with a volume that is approximately 5 
pL. Although our smallest growth chamber of 200 pL is ~40 times bigger than the macrophage 
growth chamber, it is a close approximation of the macrophage volume compared to traditional cell 
culturing system with volumes exceeding 1 mL and thus at least 200,000,000 times bigger than the 
macrophage growth chamber.  
The microdialyser 200 pL growth chamber to a macrophage growth compartment are both tiny 
growth chambers and both induce epigenetic drug tolerance to mycobacteria. We thus considered the 
plausibility that the mycobacterial drug tolerance phenotype observed in our growth chamber is of the 
same quality as the drug tolerance phenotype observed in intra-macrophage mycobacteria. For a more 











CONFINEMENT-INDUCED DRUG-TOLERANCE IN 
MYCOBACTERIA MEDIATED BY AN EFFLUX MECHANISM 
 
The next chapter consists of a manuscript a published on PloS one journal, the publication is available 
at the following link: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0136231   
Luthuli BB, Purdy GE, Balagaddé FK (2015) Confinement-Induced Drug-Tolerance in Mycobacteria 
Mediated by an Efflux Mechanism. PLoS ONE 10(8): e0136231. doi:10.1371/journal.pone.0136231 
This manuscript describes how the microdialyser chip was utilised for culturing mycobacterial cells in 
different conditions including different antimicrobial agents. We tested a number of hypothesis to 
determine the mechanism underlying drug tolerant phenomenon observed in mycobacteria growing in 














































































S1 Fig. Design and operation of the microdialysor with multiple volume reactors. (A) Optical 
micrograph of the microdialyser chip showing a single module. Scale bar, 0.5mm. The module features 8 
medium input ports, 5 cell input ports, 15 output ports and 30 individually addressable microdialyser culture 
units: six 200-, eight 500-, eight 1200 and eight 1700-picoliter cell culture chambers. The blue rectangular 
box indicates the region depicted in B, C and D. (B) Optical micrograph showing three microdialysers in a 
row to illustrate the main aspects of the microdialysis scheme. Elements such as the growth chamber, 
conditioning chamber and link valves are labelled. With the link valve closed, the conditioning chamber of 
the middle microdialyser unit is filled with blue dye (representing fresh medium). Scale bar, 0.3mm. (C) 
Once the link valve is open, diffusive exchange between the growth and conditioning chambers occurs. (D) 
After a series of (typically six) microdialysis steps, the growth chamber fluid is completely replaced with the 






S2 Fig. E. coli cells are susceptible to rifampicin in 200pL microdialysor reactors. Growth of E. coli 
Top10 F’ cells in 200 pL microdialyser reactors with switching between medium with and without 
rifampicin. The red curves represent microdialyser E. coli cultures that were initially drug-free (0 to 110hrs). 
Addition of rifampicin (350 µg/ml) at 110hrs (point A) resulted in a dramatic decrease in the cell population. 
The blue curves represent E. coli cultures that initially contained 350 µg/ml of rifampicin (0 to 110hrs). 
Removal of the drug at point A led to growth recovery in 2 of 12 cultures. All cultures were cultivated on the 






S3 Fig. Isoniazid susceptibility of M. smegmatis mc2155 cells in microdialyser reactors. Microdialyser 
drug susceptibility of mc2155 cells growing with isoniazid (40 ug/ml) in 200 pL growth chambers. 
Isoniazid inhibited growth in 8 of 11 cultures incubated in two chips. Two of the isoniazid cultures had 
minimal growth (reaching a cell surface density of 0.2) and in one growth was more significant (reaching a 







S4 Fig. Growth dynamics of M. smegmatis mc2155 cells with or without rifampicin (350 ug/ml) across 
the various microdialyser growth chambers sizes. In drug-free medium (black curves), the cells 
exhibited positive growth across all the growth chamber volumes as indicated―1700 pL,  growth in 8 of 8 
cultures; 1200 pL, growth in 8 of 8 cultures; 500 pl, growth in 7 of 7 cultures; and 200 pL, growth in 6 of 6 
cultures. With rifampicin (red curves), growth in larger reactors was inhibited―1700 pL, growth in 0 of 8 
cultures; 1200 pL, growth in 0 of 8 cultures; and 500 pL, growth in 0 of 8 cultures. In the 200 pL cultures 










S5 Fig. Functional illustration of diffusive exchange in the multi-volume microdialyser showing the 
dye concentration in the various growth chamber volumes and the conditioning chamber. The 
formulation in the conditioning chambers is cycled between DYE (cycles 2-7 and 13-19) and WATER 
(cycles 1; 8-12). The dye concentration in the various growth chambers is determined by the formulation in 
the conditioning chamber. The chamber-to-chamber variations in dye concentration are attributable to 









S6 Fig. Exponential growth rates for M. smegmatis ∆FtsEX cells growing in various growth 
chamber sizes in drug-free medium. Various growth rates were measured for bacteria growing in 
the drug-free microdialyser cultures depicted in Fig 4, however there was no significant difference 


















The Fluidic Design and Fabrication 
The chip schematic design was developed on AutoCAD software. The microdiayser chip was 
fabricated out of the silicone elastomer polyethylsiloxane (PDMS) (General Electric RTV 615) using 
multi-layer soft lithography, as described previously. Up to 120 microdialyser units can run in parallel 
on each chip. 
Calorimetric Assays 
The food dye used in the calorimetric microdialyser characterization assays was obtained from 
McCormick  Co., Hunt Valley, MD. The dye concentration in the microdialyser was determined by 
averaging the pixel values of optical micrographs of a region within the growth chamber of the 
growth chamber, conditioning chamber during a series of microdialysis steps or formulation mixing. 
Microfluidics Based DST 
Rifampicin stock solution 2 mg/ml in ethanol, Sigma Aldrich, 97% HPLC was added to sterile 7H9 
Broth medium to a final concentration of 350 µg/ml, corresponding to  approximately 10X MIC of 
mc2155. Hygromycin, isoniazid and ofloxacin dissolved in 7H9 Broth medium to create 2 mg/ml 
stock solution, which was further diluted to a final concentration of 100 µg/ml, 40 µg/ml and 100 
µg/ml, respectively. 
Before the on chip experiments, bacteria from the frozen stock were inoculated in 7H9 broth medium 
at 37C with shaking at 100 rpm. The bacteria were grown to exponential phase OD600 = 0.8. 
Approximately 150 µL of bacterial suspension was flown into the chip were 5 to 10 cells were 
trapped in each reactor. After cells have settled on chip, they were exposed to 7H9 Broth medium 
containing an antibiotic for 60 seconds every hour unless stated otherwise. In all on chip experiment, 
the chip was incubated at 37C throughout the experiment.  
Fabrication Protocol: The Microdialyser Device 
3’’ silicon wafer substrate 
Mold Fabrication 
1. Push up hybrid control molds 
Spin SU8 2010: 2500rpm x 1 min /130 second ramp up 
Film thickness = 11 microns 




1 min x 65C / 2 min x 95C 
Expose wafer: 3 s at 7 Mw/ cm2 
Post-exposure Bake: 2 min x 65C / 5 min x 95C 
Develop: 100% Shipley SU8 Nanodeveloper 
Rinse with developer 
Dry under nitrogen 
Hard Bake: 3 hours 200C 
 
Spin SU8 2015: 1500rpm x 1 min /270 second ramp up 
Film thickness = 24 microns 
Pre-exposure Bake: contact bake hotplate 
3 min x 65C / 5 min x 95C 
Expose wafer: 3.5 s at 7 Mw/ cm2 
Post-exposure Bake: 5 min x 65C / 15 min x 95C 
Develop: 100% Shipley SU8 Nanodeveloper 
Rinse with developer 
Dry under nitrogen 
 
2. Push-down control molds 
Spin SU8 2015: 1500rpm x 1 min /270 second ramp up 
Film thickness = 24 microns 
Pre-exposure Bake: contact bake hotplate 
3 min x 65C / 5 min x 95C 
Expose wafer: 3.5 s at 7 Mw/ cm2 
Post-exposure Bake: 5 min x 65C / 15 min x 95C 
Develop: 100% Shipley SU8 Nanodeveloper 
Rinse with developer 
Dry under nitrogen 
 
3. Flow hybid mold 
Spin SU9 2005: 2500 rpm x 1 min / 270 seconds ramp up 
Film thickness = 5 microns 
Pre-Exposure Bake: contact bake hotplate 
1 min x 65C / 2min x 95C 
Expose wafer: 5 s at 7 Mw/ cm2 




Rinse with fresh developer 
Dry under nitrogen 
Hard bake 3 hours 
 
Spin SU8 2010: 2500rpm x 1 min /130 second ramp up 
Film thickness = 11 microns 
Pre-exposure Bake: contact bake hotplate 
1 min x 65C / 2 min x 95C 
Expose wafer: 3 s at 7 Mw/ cm2 
Post-exposure Bake: 2 min x 65C / 5 min x 95C 
Develop: 100% Shipley SU8 Nanodeveloper 
Rinse with developer 
 
 
Priming: HDMS vapour 2 min in tuperware container 
Spin ma-p1275 positive tone resist: 1000 rpm x 1 min / 133 sec ramp up 
Film thickness = 10 microns 
Soft bake: contact bake hotplate 
90 sec x 95C 
Expose wafer: 15 s at 7Mw / cm2 
Develop:100% ma-D 531 developer 
Rinse with DI H20 
Dry under nitrogen 
Reflow: contact hotplate 
65C x 3 min / 115C x 15 min 
 
4. MSL Fabrication 
Priming: all molds 
TMCS vapor 3 min in tuperware container (STP) 
Cast Think Layer: combine 5:1 GE 615 TRV (80 g A: 16 g B) 
Mix in hybrid mixer: 5 min mix / 5 min degas 
82 g onto flow mold (petri dish lined with Al foil) 
Spin flow layer 1: combine 20:1 GE 615 RTV (20 g A: 1 g B) 
Mix hybrid mixer: 5 min mix / 5 min degas 
Dispense 5 mL on flow layer 




1st Cure Thick Layer: convention oven 
80 C for 45 min 
Punching push down control input holes: peel thick layer from mold 
Punch flow input holes 
Align to spin-coated and cured flow layer mold 
Bake in convention oven 
80C x 45 min 
Spin push-up control layer: combine 20:1 GE 615 RTV (20 g A: 1 g B) 
Mix hybrid mixer: 5 min mix / 2 min degas 
Dispense 5 Ml on flow layer 
1800 rpm x 60 sec / 15 s ramp 
1st cure push-up control Layer: convection oven 
80C x 45 min 
Control/flow/control bonding: peel thick / flow bonded layer from 
Take care to not rip membranes 
Punch flow input and output port holes 
Align to spin-coated and cured push-up control layer 
Ensure no air bubbles under membranes 
Ensure to collapse no valves 
Bake in convection oven 
80C x 45 min 
 
Spin blank layer: combine 30:1 GE 615 RTV (30 g A: 1 g B) 
Mix hybrid mixer: 5 min mix / 5 min degas 
Dispense 5 Ml clean glass substrate 
1800 rpm x 60 s / 15 s ramp 
1st cure blank layer: convection oven 
80C x 60 min 
Control / flow / control / blank bonding: peel control 1 / flow / control / control 2 bonded 
layer from mold 
Take care to not rip membranes 
Punch control 2 (push-up) input port holes 
Align to spin-coated and cured blank mold 
Ensure no air bubbles under membranes 
Ensure no collapsed valves 




80C x 8 hours 
 
Matlab Image Processing script 
%%%%% Bonisile Luthuli 
%%%%  28 October 2013 
%%%%  GROWTH CURVES 




source_dir = 'I:\users\bonisile\shots\D30Oct2014_12_05\R1C1' 
excel_name = 'reactor 1.xls'; 
  
%%% READING ALL IMAGES IN A DIRECTORY             
all_images = 'PH_Raw*.lvm';            
lvm_image_file_path = strcat(source_dir,'\',all_images);             
my_source_lvm_files_struct = dir(lvm_image_file_path);            
item_size = size(my_source_lvm_files_struct);             





% im11 = 10; %1 
% im22 = 62; %fsize 
  
im11 = 1; %1  9... 59 
im22 = 217; %fsize 
  
%%%% Change 1 
thresh = 0.6; %%%%0.6 
thrash = 0.45; %0.6; 
  
%%%% Adjustments 




bgndMultFactor = 15;  %%%%15 
FilterAve = 8;  %%%8 
AdjustThresh = 0.0018;  %%%0.0018 
bwSize = 250; %%300 
  
  
for rois = 1:1 
    for image = im11:im22  %1:fsize  39      
        display_str = strcat('image ',num2str(image)) 
         
        filename = my_source_lvm_files_struct(image).name; 
        filename_path = strcat(source_dir,'\', filename); 
        LV_Image_All = dlmread(filename_path, '\t');  
        %Temp_LV_Image_pre = imcrop(immultiply(LV_Image_All, 0.0001),positionF);%0.00030    
        %Temp_LV_Image_pre = imcrop(imadjust(immultiply(LV_Image_All, 
0.0001)),positionF);%0.00030  
         
        Temp_LV_Image_pre1 = imadjust(immultiply(LV_Image_All, 0.0001));%0.00010  
         
         
        if(image == im11) 
             
            %% read one image 
             
            figure, imshow(Temp_LV_Image_pre1 ); 
  
            piece = imrect; 
            positionF1 = wait(piece); 
  
            piece2 = imrect; 
            positionF2 = wait(piece2);                               
             
        end 
         
        Temp_LV_Image_pre2 = Temp_LV_Image_pre1; 
        size_new = size(Temp_LV_Image_pre2); 




        sy = size_new(2); 
  
        for xit = 1:sx 
            for yit = 1:sy 
                if(Temp_LV_Image_pre2(xit,yit) > thresh) 
                    Temp_LV_Image_pre2(xit,yit) = thrash; 
                end  
            end 
        end 
         
         
        Temp_LV_Image_pre = Temp_LV_Image_pre2;%0.00030    
         
        complement_image = immultiply(imcomplement(Temp_LV_Image_pre),1); %0.5 
     
        % %%%% REMOVE BACKGROUND 
        %%%% Change 2: (complement_image,strel('disk',Change)): 4 to 12 
        background = imopen(complement_image,strel('disk',bgndThresh));%8, 12 
         
        %%% change 3 
        subtract_background = immultiply((complement_image-background),bgndMultFactor); %15, 50 
     
        %%%% Change 4 
        H = filter2(fspecial('average', FilterAve),subtract_background)/255; %8 
         
        %%%% Change 5 
        J = imadjust(H, [AdjustThresh 1], [0 1]);  %0.2 0.01, 0.0001 
        K=graythresh(J); 
        L = im2bw(J,K); 
         
        %%%% Change 6 
        Lbw = bwareaopen(L, bwSize); %150 
         
        Lbw1 = imcrop(Lbw, positionF1); 
        Lbw2 = imcrop(Lbw, positionF2); 
         




        Or2 = imcrop(Temp_LV_Image_pre1, positionF2); 
         
        filename_path1 = strcat(source_dir,'\Proc_Im_', num2str(image),'_1.png'); 
        filename_path2 = strcat(source_dir,'\Proc_Im_', num2str(image),'_2.png'); 
         
        filename_path3 = strcat(source_dir,'\Proc_Im_', num2str(image),'_Or_1.png'); 
        filename_path4 = strcat(source_dir,'\Proc_Im_', num2str(image),'_Or_2.png'); 
         
        imwrite(Or1,filename_path3); 
        imwrite(Or2,filename_path4); 
         
        imwrite(Lbw1,filename_path1); 
        imwrite(Lbw2,filename_path2); 
         
         
         
        my_data(image) = sum(sum(Lbw1)) + sum(sum(Lbw2)); 
         
         
         
        %%%% Get Image Date Info 
        my_strng = my_source_lvm_files_struct(image).date; %%%'25-Oct-2013 17:40:14'; 
        day1 = strtok(my_strng,'-'); 
        day = str2num(day1); 
        [token,remain] = strtok(my_strng,'-'); 
        mystrng2 = [remain]; 
        mnth = strtok(mystrng2,'-'); 
        month = str2num(mnth); 
        [token,remain] = strtok(mystrng2,'-'); 
        mystrng3 = [remain]; 
        yr1 = strtok(mystrng3,' '); 
        yr =strrep(yr1,'-',''); 
        year = str2num(yr); 
        [token,remain] = strtok(mystrng3,' '); 
        mystrng4 = [remain]; 
        hr = strtok(mystrng4,':'); 




        [token,remain] = strtok(mystrng4,':'); 
        mystrng5 = [remain]; 
        mins = strtok(mystrng5,':'); 
        minutes = str2num(mins); 
        [token,remain] = strtok(mystrng5,':'); 
        seconds1 = [remain]; 
        u = strrep(seconds1,':',''); 
        seconds = str2num(u); 
    
        % month ='Jan' 
    
        switch mnth 
            case 'Jan' 
                month_num = 1; 
                month_days = 31; 
            case 'Feb' 
                month_num = 2; 
                month_days = 28; 
            case 'Mar' 
                month_num = 3; 
                month_days = 31; 
            case 'Apr'  
                month_num = 4; 
                month_days = 30; 
            case 'May'  
                month_num = 5; 
                month_days = 31 
            case 'Jun'  
                month_num = 6; 
                month_days = 30; 
            case 'Jul'  
                month_num = 7; 
                month_days = 31; 
            case 'Aug'  
                month_num = 8; 
                month_days = 31; 




                month_num = 9; 
                month_days = 30  
            case 'Oct'                
                month_num = 10;         
                month_days = 31;     
            case 'Nov'        
                month_num = 11;         
                month_days = 30;     
            case 'Dec'         
                month_num = 12;         
                month_days = 31 
        end 
    
        %month_num 
        y = year*24*month_days*12; 
        m = month_num*24*month_days; 
        d = day*24; 
        h = hour; 
        m = minutes/60; 
        s = seconds/3600; 
        date_number = y+m+d+h+m+s; 
    
        %%  End of Image Date 
        my_time(image) = date_number; 
    end 
end 
  
for t = im11:im22    %1:fsize 
    my_time_zero(t) = my_time(t) - my_time(1); 
end 
  
%%%% write to excel%%%%% 
  
excel_file = strcat(source_dir,'\',excel_name); 
  





fprintf(FID,'Count \t my_time_zero(t) \t bw data \t log bw data \n'); 
  
for it= im11:im22 %1:fsize 
    fprintf(FID,'%g \t',it); 
    fprintf(FID,'%g \t',my_time_zero(it)); 
     
    to_data1 = my_data(it); 
    fprintf(FID,'%g \t',to_data1); 
     
    log_data1 = log(to_data1); 
    fprintf(FID,'%g \n',log_data1); 































 CONCLUDING REMARKS 
Here we successfully created the microdialyser chip, a culture-based drug susceptibility test for 
tuberculosis. The purpose of this design was to grow mycobacterial cells in different micro-reactors 
and study the effects of antibiotics through time lapse microscopy. We used M. smegmatis as a 
surrogate for M. tuberculosis. The microdialyser enabled mycobacterial culturing whose growth was 
observed via time lapsed microscopy. We further exposed trapped mycobacterial in miniaturized 
bioreactors of the microdialyser chip to a series of antibiotics where we observed antibiotic-induced 
cell death and tolerance in real time using this device. 
Interestingly we repeatedly observed rifampicin tolerance to mycobacteria growing in space confined 
bioreactors (200 pL), but disappeared in larger contexts. Interestingly this drug tolerant phenomenon 
has been observed in mycobacteria growing inside the macrophage suggesting that the 
microenvironment created in the microdialyser mimics that observed in vivo. We then tested a number 
of hypothesis which suggested that an active efflux pump mediates rifampicin tolerance in 
mycobacteria cultured in miniaturised bioreactors. Although some studies have mentioned that efflux 
mechanism may be induced by macrophages, our results suggest that the size in which the 
mycobacterial cells are growing in, induces drug tolerance. We now know that more than one active 
pump is involved in expulsion of rifampicin from mycobacterial cells because efflux pump inhibitors 
reduced tolerance. In addition, MmpL11―a membrane protein involved in lipid transport seems to 
contribute. 
Our data suggest that confinement induced rifampicin tolerance in the 200 pL growth chamber was 
mediated by an efflux mechanism which expelled rifampicin from the mycobacterial cells. Because 
drug tolerance was not observed in the case of drugs such as ofloxacin and hygromycin, it is plausible 
that the efflux pump responsible for rifampicin tolerance is specific to expulsion of rifampicin from 
the mycobacterial cell and not the other antibiotics in this case hygromycin and ofloxacin. From the 
current experimental data, this is our best explanation for the growth inhibitory effect of hygromycin 
and ofloxacin in the 200 pL growth chambers. Although there are efflux pumps that extrude a variety 
of structurally diverse antibiotics called multiple drug resistant pumps which might not have been 





I did not plate the mycobacteria from the 200 pL due to the limitations of the current chip that prevent 
retrieval of the microbial cells from the chip. However, I, performed an experiment in which I 
switched the medium feed from rifampicin containing medium to drug free medium in the bigger 
growth chambers. We observed that although growth was suppressed by medium containing 
rifampicin, growth resumed when the medium was replaced with drug-free medium revealing the 
bacteriostatic nature of rifampicin. The only experiment related to this was first culturing 
mycobacteria in the growth chamber 200 pL for 60 hours, when the mycobacteria had reached 
exponential phase, about 5 bacteria from the 200 pL were then moved to seed the adjacent 
conditioning chamber which is bigger (800 pL) than the growth chamber. And from this experiment 
we observed suppressed growth suggesting that mycobacteria produce different phenotypes in 
different environments. Our experiments do not dispute the plausibility that hygromycin and ofloxacin 
are bacteriostatic since the above experiment was not performed on these drugs.  
The microdialyser chip should be further investigated as possible alternative to a more authentic DST 
that better test mimics the in vivo environment encountered by the tubercle bacilli in lungs, compared 
to conventional cell culture methods. This is especially important given that conventional cultures 
performed on plates and liquid medium are poor predictors of in vivo drug efficacy. 
Our experiments suggest a quorum sensing mechanism involved in activation of the efflux pumps. 
Quorum sensing molecules are expected to be highly concentrated in a space confined environment 
and may play a role in induction of rifampicin toleranceone of the major first-line anti-TB drugs. 
Since quorum sensing has been involved in critical mechanisms of microorganisms such as 
pathogenesis, virulence and development of biofilms it is highly possible that they can also be one of 
the microbial defence mechanisms aimed at neutralizing the effect of antibiotics. 
Future Direction  
To further investigate the effect of quorum sensing on mycobacteria, the idea would be to improve the 
current chip design to enable recovery of medium from the growth chamber for chemical analysis. 
This would enable us to perform experiments to measure the proposed quorum sensing molecules 
release by mycobacteria responsible for drug tolerance. We could also add generic quorum quenchers 
to the cell cultures to observe their effect on mycobacteria drug tolerance in the small growth 
chambers. The chip would also enable recovery of cells from the growth chamber to perform single 
cell transcriptomics to look for different gene expression profiles in the susceptible versus non-
susceptible populations and adapt this system to TB susceptibility testing. 
Further clinical applicability of our system will depend upon validation with various strains of M. 
tuberculosis. The next phase will be to culture M. tuberculosis isolates in the microdialyser system. 




fully automated, protective to the user from infectious strains of M. tuberculosis. This system will be 
relatively faster than current drug susceptibility testing methods by culture by minimizing the time 
required for colony forming units (CFU). We will also operationalise the formulator ring for 
automated combinatorial drug mixing, which will shield the user away from preparing multiple drug 
solutions. 
This system would be more useful in resource-limited settings where point-of-care diagnostic tools 
are needed the most. Resource-limited settings are mostly situated I remote areas with one clinic 
serving large geographical areas, far away from diagnostics laboratories. A more portable (point-of-
care) diagnostic test for TB would make the results easily accessible in every clinic within the 
community, and eliminate the need for sample transportation. 
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